Neuronetics (STIM) 8-K/A 6 Feb 25 Financial Statements and Exhibits Financial data

Cover Page

Cover Page	Dec. 10, 2024
Cover [Abstract]
Amendment Flag	true
Entity Central Index Key	0001227636
Document Type	8-K/A
Document Period End Date	Dec. 10, 2024
Entity Registrant Name	NEURONETICS, INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-38546
Entity Tax Identification Number	33-1051425
Entity Address, Address Line One	3222 Phoenixville Pike
Entity Address, City or Town	Malvern
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19355
City Area Code	610
Local Phone Number	640-4202
Title of 12(b) Security	Common Stock ($0.01 par value)
Trading Symbol	STIM
Security Exchange Name	NASDAQ
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Amendment Description	As previously disclosed in the Current Reports on Form 8-K filed by Neuronetics, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”), the Company entered into an arrangement agreement on August 11, 2024 with Greenbrook TMS Inc. (“Greenbrook”), pursuant to which the Company agreed to acquire all of the issued and outstanding common shares of Greenbrook pursuant to a plan of arrangement under the Business Corporations Act (Ontario) (the “Arrangement”). The Arrangement was effective as of December 9, 2024. This Amendment No. 1 on Form 8-K/A is being filed to amend Item 9.01(a) and (b) of the Current Report on Form 8-K that the Company filed with the SEC on December 10, 2024, regarding the completion of its acquisition of Greenbrook to include the historical financial statements of Greenbrook required by Item 9.01(a) of Form 8-K and the pro forma financial information required by Item 9.01(b) of Form 8-K.

Condensed Interim Consolidated

Condensed Interim Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash	$ 368,512	$ 3,323,708
Restricted cash	1,000,000	1,000,000
Accounts receivable, net	12,628,278	7,569,843
Prepaid expenses and other	5,647,935	3,079,785
Total current assets	19,644,725	14,973,336
Property, plant and equipment	4,725,435	4,793,979
Intangible assets	572,537	622,057
Finance right-of-use assets	1,276,821	2,140,338
Operating right-of-use assets	23,658,188	28,887,905
Total assets	49,877,706	51,417,615
Current liabilities:
Accounts payable	10,563,496	9,050,616
Accrued expenses	14,948,703	13,701,630
Current portion of loans payable	11,419,486	5,770,603
Current portion of finance lease liabilities	355,161	622,730
Current portion of operating lease liabilities	4,043,583	3,960,346
Current portion of shareholder loans	3,690,568	505,161
Other payables	1,947,395	5,730,781
Non-controlling interest loans	58,074	63,174
Deferred and contingent consideration	1,000,000	1,000,000
Advance for research collaboration		1,300,000
Total current liabilities	37,462,970	32,654,425
Loans payable	131,774,065	90,230,173
Finance lease liabilities	20,534	235,107
Operating lease liabilities	21,138,829	26,438,220
Shareholder loans		2,807,480
Total liabilities	190,396,398	152,365,405
Commitments and contingencies
Shareholders' deficit:
Common shares	121,236,710	120,741,061
Contributed surplus	5,508,810	5,397,700
Deficit	(263,661,144)	(224,174,970)
Total shareholders' deficit excluding non-controlling interest	(136,915,624)	(98,036,209)
Non-controlling interest	(3,603,068)	(2,911,581)
Total shareholders' deficit	(140,518,692)	(100,947,790)
Total liabilities and shareholders' deficit	49,877,706	$ 51,417,615
Neuronetics [Member]
Current assets:
Cash	20,867,000
Restricted cash	0
Accounts receivable, net	16,825,000
Inventory	4,960,000
Current portion of net investments in sales-type leases	572,000
Current portion of prepaid commission expense	2,921,000
Current portion of notes receivable	2,477,000
Prepaid expenses and other	4,837,000
Total current assets	53,459,000
Property, plant and equipment	1,639,000
Intangible assets	0
Finance right-of-use assets	0
Operating right-of-use assets	2,328,000
Net investments in sales-type leases	140,000
Prepaid commission expense	8,733,000
Long-term notes receivable	2,878,000
Goodwill	0
Other assets	4,940,000
Total assets	74,117,000
Current liabilities:
Accounts payable	3,295,000
Accrued expenses	11,429,000
Deferred revenue	1,311,000
Current portion of finance lease liabilities	0
Current portion of operating lease liabilities	862,000
Current portion of shareholder loans	0
Current portion of long-term debt, net:	0
Non-controlling interest loans	0
Deferred and contingent consideration	0
Current portion of shareholder note	0
Total current liabilities	16,897,000
Long-term debt, net	46,002,000
Deferred revenue	4,000
Operating lease liabilities	1,833,000
Total liabilities	64,736,000
Commitments and contingencies	0
Shareholders' deficit:
Preferred stock, $0.01 par value: 10,000 shares authorized; no shares issued or outstanding on September 30, 2024	0
Common shares	303,000
Deficit	(407,127,000)
Additional paid-in capital	416,205,000
Non-controlling interest	0
Total shareholders' deficit	9,381,000
Total liabilities and shareholders' deficit	74,117,000
Greenbook [Member]
Current assets:
Cash	369,000
Restricted cash	1,000,000
Accounts receivable, net	12,628,000
Inventory	0
Current portion of net investments in sales-type leases	0
Current portion of prepaid commission expense	0
Current portion of notes receivable	0
Prepaid expenses and other	5,648,000
Total current assets	19,645,000
Property, plant and equipment	4,725,000
Intangible assets	573,000
Finance right-of-use assets	1,277,000
Operating right-of-use assets	23,658,000
Net investments in sales-type leases	0
Prepaid commission expense	0
Long-term notes receivable	0
Goodwill	0
Other assets	0
Total assets	49,878,000
Current liabilities:
Accounts payable	10,564,000
Accrued expenses	4,385,000
Deferred revenue	0
Current portion of finance lease liabilities	355,000
Current portion of operating lease liabilities	4,044,000
Current portion of shareholder loans	3,691
Current portion of long-term debt, net:	11,420,000
Other payables	1,947,000
Non-controlling interest loans	58
Deferred and contingent consideration	1,000,000
Current portion of shareholder note	0
Total current liabilities	37,463,000
Long-term debt, net	131,774,000
Finance lease liabilities	21,000
Operating lease liabilities	21,139,000
Total liabilities	190,396,000
Commitments and contingencies	0
Shareholders' deficit:
Preferred stock, $0.01 par value: 10,000 shares authorized; no shares issued or outstanding on September 30, 2024	0
Common shares	121,237,000
Deficit	(263,661,000)
Additional paid-in capital	5,509,000
Non-controlling interest	(3,603,000)
Total shareholders' deficit	(136,915,000)
Total liabilities and shareholders' deficit	49,878,000
Transaction Accounting Adjustment [Member]
Current assets:
Cash	0
Restricted cash	0
Accounts receivable, net	(1,891,000)
Inventory	0
Current portion of net investments in sales-type leases	(351,000)
Current portion of prepaid commission expense	0
Current portion of notes receivable	(1,557,000)
Prepaid expenses and other	(702,000)
Total current assets	(4,501,000)
Property, plant and equipment	370,000
Intangible assets	(573,000)
Finance right-of-use assets	(1,277,000)
Operating right-of-use assets	0
Net investments in sales-type leases	(19,000)
Prepaid commission expense	0
Long-term notes receivable	(2,335,000)
Goodwill	23,803,000
Other assets	0
Total assets	15,468,000
Current liabilities:
Accounts payable	(1,891,000)
Accrued expenses	0
Deferred revenue	(192,000)
Current portion of finance lease liabilities	(355,000)
Current portion of operating lease liabilities	0
Current portion of shareholder loans	(3,691)
Current portion of long-term debt, net:	(11,210,000)
Other payables	(1,414,000)
Non-controlling interest loans	0
Deferred and contingent consideration	0
Current portion of shareholder note	0
Total current liabilities	(18,753,000)
Long-term debt, net	(131,774,000)
Deferred revenue	0
Finance lease liabilities	(21,000)
Operating lease liabilities	0
Total liabilities	(150,548,000)
Commitments and contingencies
Shareholders' deficit:
Preferred stock, $0.01 par value: 10,000 shares authorized; no shares issued or outstanding on September 30, 2024	0
Common shares	(120,984,000)
Deficit	263,661,000
Additional paid-in capital	23,339,000
Non-controlling interest	0
Total shareholders' deficit	166,016,000
Total liabilities and shareholders' deficit	15,468,000
Pro Forma [Member]
Current assets:
Cash	21,236,000
Restricted cash	1,000,000
Accounts receivable, net	27,562,000
Inventory	4,960,000
Current portion of net investments in sales-type leases	221,000
Current portion of prepaid commission expense	2,921,000
Current portion of notes receivable	920,000
Prepaid expenses and other	9,783,000
Total current assets	68,603,000
Property, plant and equipment	6,734,000
Intangible assets	0
Finance right-of-use assets	0
Operating right-of-use assets	25,986,000
Net investments in sales-type leases	121,000
Prepaid commission expense	8,733,000
Long-term notes receivable	543,000
Goodwill	23,803,000
Other assets	4,940,000
Total assets	139,463,000
Current liabilities:
Accounts payable	11,968,000
Accrued expenses	15,814,000
Deferred revenue	1,119,000
Current portion of finance lease liabilities	0
Current portion of operating lease liabilities	4,906,000
Current portion of shareholder loans	0
Current portion of long-term debt, net:	209,000
Other payables	533,000
Non-controlling interest loans	58
Deferred and contingent consideration	1,000,000
Current portion of shareholder note	0
Total current liabilities	35,607,000
Long-term debt, net	46,002,000
Deferred revenue	4,000
Finance lease liabilities	0
Operating lease liabilities	22,972,000
Total liabilities	104,585,000
Commitments and contingencies
Shareholders' deficit:
Preferred stock, $0.01 par value: 10,000 shares authorized; no shares issued or outstanding on September 30, 2024	0
Common shares	556,000
Deficit	(407,127,000)
Additional paid-in capital	445,053,000
Non-controlling interest	(3,603,000)
Total shareholders' deficit	38,482,000
Total liabilities and shareholders' deficit	$ 139,463,000

Condensed Interim Consolidate_2

Condensed Interim Consolidated Balance Sheets (Parenthectical)	Sep. 30, 2024 $ / shares shares
Common Stock, Shares, Outstanding	33,967,600
Common Stock [Member]
Common Stock, Shares, Issued	33,967,600
Pro Forma [Member] | Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 0.01
Preferred Stock, Shares Authorized	10,000
Preferred Stock, Shares Issued	0
Preferred Stock, Shares Outstanding	0
Pro Forma [Member] | Common Stock [Member]
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.01
Common Stock, Shares Authorized	200,000
Common Stock, Shares, Issued	55,622
Common Stock, Shares, Outstanding	55,622

Condensed Interim Consolidate_3

Condensed Interim Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue:
Revenue	$ 19,072,131	$ 17,364,264	$ 57,492,388	$ 54,359,174
Expenses:
Direct center and patient care costs	13,043,838	13,135,231	39,945,827	40,397,958
Other regional and center support costs	7,223,389	4,764,130	20,645,033	14,353,697
Depreciation	308,113	583,388	932,061	2,418,742
Total	20,575,340	18,482,749	61,522,921	57,170,397
Regional operating loss	(1,503,209)	(1,118,485)	(4,030,533)	(2,811,223)
Center development costs	31,929	137,770	272,650	355,832
Corporate, general and administrative expenses	6,291,658	5,986,061	21,470,073	21,405,122
Share-based compensation	51,923	14,740	111,110	591,470
Amortization	16,426	16,548	49,520	49,643
Interest expense	4,984,262	3,088,382	13,921,621	8,665,931
Interest income	(66)	(64)	(196)	(165)
Loss on extinguishment of loans		14,274	(39,822)	14,274
Loss on device contract termination		3,181,116		3,181,116
Loss before income taxes	(12,879,341)	(13,557,312)	(39,855,311)	(37,074,446)
Income tax expense	0	0	0	0
Loss for the period and comprehensive loss	(12,879,341)	(13,557,312)	(39,855,311)	(37,074,446)
Non-controlling interest	328,018	(66,025)	(24,461)	(249,575)
Loss for the period and comprehensive loss attributable to Greenbrook	$ (13,207,359)	$ (13,491,287)	$ (39,830,850)	$ (36,824,871)
Net loss per share:
Basic	$ (0.33)	$ (0.32)	$ (0.92)	$ (0.97)
Diluted	$ (0.33)	$ (0.32)	$ (0.92)	$ (0.97)
Service revenue
Revenue:
Revenue	$ 18,872,131	$ 17,364,264	$ 55,992,388	$ 54,359,174
Other revenue
Revenue:
Revenue	$ 200,000		$ 1,500,000

Condensed Interim Consolidate_4

Condensed Interim Consolidated Statements of Operations - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Revenues	$ 57,492,388
Regional operating loss	(4,030,533)
Operating expenses:
General and administrative	21,470,073
Research and development	272,650
Other (income) expense:
Interest expense	(13,921,621)
Gain (Loss) on Extinguishment of Debt	39,822
Non-controlling interest	(24,461)
Loss for the period and comprehensive loss attributable to Greenbrook	$ (39,830,850)
Net loss per share of common stock outstanding, basic	$ (0.92)
Net loss per share of common stock outstanding, diluted	$ (0.92)
Weighted average common shares outstanding, basic (in shares)	43,061,687
Weighted average common shares outstanding, diluted (in shares)	43,061,687
Neuronetics [Member]
Revenues	$ 52,397,000	$ 71,348,000
Cost of revenues	13,129,000	19,643,000
Regional operating loss	39,268,000	51,705,000
Operating expenses:
Sales and marketing	35,820,000	47,318,000
General and administrative	19,540,000	25,426,000
Research and development	6,999,000	9,515,000
Total operating expenses	62,359,000	82,259,000
Loss from operations	(23,091,000)	(30,554,000)
Other (income) expense:
Interest expense	5,529,000	5,424,000
Gain (Loss) on Extinguishment of Debt	4,427,000
Other income, net	(2,001,000)	(5,789,000)
Net loss before non-controlling interest	(31,046,000)	(30,189,000)
Non-controlling interest		0
Loss for the period and comprehensive loss attributable to Greenbrook	$ (31,046,000)	$ (30,189,000)
Net loss per share of common stock outstanding, basic	$ (1.04)	$ (1.05)
Net loss per share of common stock outstanding, diluted	$ (1.04)	$ (1.05)
Weighted average common shares outstanding, basic (in shares)	29,931	28,658
Weighted average common shares outstanding, diluted (in shares)	29,931	28,658
Greenbook [Member]
Revenues	$ 57,492,000	$ 73,787,000
Cost of revenues	56,649,000	71,872,000
Regional operating loss	843,000	1,915,000
Operating expenses:
Sales and marketing	3,942,000	1,945,000
General and administrative	22,563,000	33,056,000
Research and development	273,000	526,000
Total operating expenses	26,777,000	35,526,000
Loss from operations	(25,934,000)	(33,611,000)
Other (income) expense:
Interest expense	13,921,000	12,048,000
Gain (Loss) on Extinguishment of Debt	0
Other income, net	0	3,596,000
Net loss before non-controlling interest	(39,855,000)	(49,255,000)
Non-controlling interest	(24,000)	(341,000)
Loss for the period and comprehensive loss attributable to Greenbrook	(39,831,000)	(48,914,000)
Transaction Accounting Adjustment [Member]
Revenues	(7,119,000)	(10,395,000)
Cost of revenues	(17,011,000)	(22,169,000)
Regional operating loss	9,892,000	11,774,000
Operating expenses:
Sales and marketing	10,022,000	10,864,000
General and administrative	0	0
Research and development	0	0
Total operating expenses	10,022,000	10,864,000
Loss from operations	(130,000)
Other (income) expense:
Interest expense	(13,897,000)	(12,016,000)
Gain (Loss) on Extinguishment of Debt	452,000
Other income, net	0	556,000
Net loss before non-controlling interest	13,316,000	11,460,000
Non-controlling interest	0	0
Loss for the period and comprehensive loss attributable to Greenbrook	$ 13,316,000	11,460,000
Weighted average common shares outstanding, basic (in shares)	25,305
Weighted average common shares outstanding, diluted (in shares)	25,305
Pro Forma [Member]
Revenues	$ 102,771,000	134,740,000
Cost of revenues	52,767,000	69,346,000
Regional operating loss	50,004,000	65,394,000
Operating expenses:
Sales and marketing	49,784,000	60,126,000
General and administrative	42,103,000	58,482,000
Research and development	7,272,000	10,041,000
Total operating expenses	99,158,000	128,649,000
Loss from operations	(49,155,000)	(63,255,000)
Other (income) expense:
Interest expense	5,553,000	5,456,000
Gain (Loss) on Extinguishment of Debt	4,879,000
Other income, net	(2,001,000)	(1,637,000)
Net loss before non-controlling interest	(57,586,000)	(67,073,000)
Non-controlling interest	(24,000)	(341,000)
Loss for the period and comprehensive loss attributable to Greenbrook	$ (57,561,000)	$ (66,732,000)
Net loss per share of common stock outstanding, basic	$ (1.04)	$ (1.24)
Net loss per share of common stock outstanding, diluted	$ (1.04)	$ (1.24)
Weighted average common shares outstanding, basic (in shares)	55,236	53,963
Weighted average common shares outstanding, diluted (in shares)	55,236	53,963

Condensed Interim Consolidate_5

Condensed Interim Consolidated Statements of Changes in Equity (Deficit) - USD ($)	Total	Common shares	Contributed surplus	Deficit	Non-controlling interest
Balance at the beginning at Dec. 31, 2022	$ (59,111,842)	$ 114,120,362	$ 4,552,067	$ (175,007,144)	$ (2,777,127)
Balance at the beginning (in shares) at Dec. 31, 2022		29,436,545
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net comprehensive loss for the period	(10,660,136)			(10,591,310)	(68,826)
Share-based compensation (note 15)	62,948		62,948
Issuance of common shares (note 14)	6,139,262	$ 6,139,262
Issuance of common shares (note 14) (in shares)		11,363,635
Issuance of lender warrants	59,786		59,786
Acquisition of subsidiary non-controlling interest (note 23)				(118,052)	118,052
Balance at the end at Mar. 31, 2023	(63,509,982)	$ 120,259,624	4,674,801	(185,716,506)	(2,727,901)
Balance at the end (in shares) at Mar. 31, 2023		40,800,180
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net comprehensive loss for the period	(12,856,998)			(12,742,274)	(114,724)
Share-based compensation (note 15)	513,782		513,782
Balance at the end at Jun. 30, 2023	(75,853,198)	$ 120,259,624	5,188,583	(198,458,780)	(2,842,625)
Balance at the end (in shares) at Jun. 30, 2023		40,800,180
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net comprehensive loss for the period	(13,557,312)			(13,491,287)	(66,025)
Share-based compensation (note 15)	14,740		14,740
Issuance of common shares (note 14)	481,437	$ 481,437
Issuance of common shares (note 14) (in shares)		1,973,831
Issuance of lender warrants	19,346		19,346
Acquisition of subsidiary non-controlling interest (note 23)	(513)			371,303	(371,816)
Gain on extinguishment of shareholder loan	39,822		39,822
Distributions to non-controlling interest	(20,000)			(20,000)
Balance at the end at Sep. 30, 2023	(88,875,678)	$ 120,741,061	5,262,491	(211,598,764)	(3,280,466)
Balance at the end (in shares) at Sep. 30, 2023		42,774,011
Balance at the beginning at Dec. 31, 2023	(100,947,790)	$ 120,741,061	5,397,700	(224,174,970)	(2,911,581)
Balance at the beginning (in shares) at Dec. 31, 2023		42,774,011
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net comprehensive loss for the period	(14,540,145)			(14,218,296)	(321,849)
Share-based compensation (note 15)	25,302		25,302
Issuance of common shares (note 14)	495,649	$ 495,649
Issuance of common shares (note 14) (in shares)		2,828,249
Balance at the end at Mar. 31, 2024	(114,966,984)	$ 121,236,710	5,423,002	(238,393,266)	(3,233,430)
Balance at the end (in shares) at Mar. 31, 2024		45,602,260
Balance at the beginning at Dec. 31, 2023	(100,947,790)	$ 120,741,061	5,397,700	(224,174,970)	(2,911,581)
Balance at the beginning (in shares) at Dec. 31, 2023		42,774,011
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common shares (note 14)	$ 495,649
Issuance of common shares (note 14) (in shares)	2,828,249
Balance at the end at Sep. 30, 2024	$ (140,518,692)	$ 121,236,710	5,508,810	(263,661,144)	(3,603,068)
Balance at the end (in shares) at Sep. 30, 2024		33,967,600
Balance at the beginning at Mar. 31, 2024	(114,966,984)	$ 121,236,710	5,423,002	(238,393,266)	(3,233,430)
Balance at the beginning (in shares) at Mar. 31, 2024		45,602,260
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net comprehensive loss for the period	(12,435,825)			(12,405,195)	(30,630)
Share-based compensation (note 15)	33,885		33,885
Acquisition of subsidiary non-controlling interest (note 23)	(121,350)			344,676	(466,026)
Distributions to non-controlling interest	(94,500)				(94,500)
Balance at the end at Jun. 30, 2024	(127,584,774)	$ 121,236,710	5,456,887	(250,453,785)	(3,824,586)
Balance at the end (in shares) at Jun. 30, 2024		45,602,260
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net comprehensive loss for the period	(12,879,341)			(13,207,359)	328,018
Share-based compensation (note 15)	51,923		51,923
Distributions to non-controlling interest	(106,500)				(106,500)
Surrender and cancellation of common shares – PA Settlement Agreement (note 14)		(11,634,660)
Balance at the end at Sep. 30, 2024	$ (140,518,692)	$ 121,236,710	$ 5,508,810	$ (263,661,144)	$ (3,603,068)
Balance at the end (in shares) at Sep. 30, 2024		33,967,600

Condensed Interim Consolidate_6

Condensed Interim Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Operating activities:
Loss for the period	$ (12,879,341)	$ (13,557,312)	$ (39,855,311)	$ (37,074,446)
Adjusted for:
Amortization			49,520	49,643
Depreciation			932,061	2,418,742
Operating lease expense			5,494,188	6,061,923
Interest expense	4,984,262	3,088,382	13,921,621	8,665,931
Interest income	(66)	(64)	(196)	(165)
Share-based compensation			111,110	591,470
Loss on extinguishment of loan		14,274	(39,822)	14,274
Loss on device contract termination (note 11(d))		3,181,116		3,181,116
Credit facility amendment fee (note 9(a))				1,000,000
Neuronetics Note non-cash transaction costs (note 9(a))				116,356
Gain on lender warrants				(6,567)
Gain on deferred share units (note 11(b))			(333,105)	(273,938)
Gain on performance share units				(43,748)
Change in non-cash operating working capital:
Accounts receivable			(5,058,435)	1,131,874
Prepaid expenses and other			(2,568,150)	(1,663,270)
Accounts payable and accrued liabilities			1,247,073	7,286,486
Other payables			(3,449,234)	(750,000)
Advance for research collaboration			(1,300,000)
Interest paid			(575,655)	(2,906,444)
Interest received			196	165
Repayment of operating lease liabilities			(5,425,421)	(8,024,282)
Operating activities			(36,809,738)	(20,224,880)
Financing activities:
Net proceeds on issuance of common shares (note 14)			495,649	6,620,699
Financing costs incurred			(733,275)	(702,403)
Loans payable advanced (note 9(a))			36,218,275	9,299,000
Loans payable and promissory notes repaid (note 9(a))			(1,252,265)	(655,343)
Promissory notes advanced (note 9(a) and note 10)				8,100,000
Principal repayment of finance lease liabilities			(541,492)	(3,168,061)
Net non-controlling interest loans repaid			(10,000)	(17,027)
Distribution to non-controlling interest			(201,000)	(20,000)
Financing activities			33,975,892	19,456,865
Investing activities:
Purchase of property, plant and equipment				(43,143)
Acquisition of subsidiary non-controlling interest (note 23)			(121,350)	(513)
Investing activities			(121,350)	(43,656)
Increase (decrease) in cash			(2,955,196)	(811,671)
Cash, beginning of period			3,323,708	1,623,957	$ 1,623,957
Cash, end of period	$ 368,512	$ 812,286	$ 368,512	$ 812,286	$ 3,323,708

Reporting Entity

Reporting Entity	9 Months Ended
	Sep. 30, 2024
Reporting Entity
Reporting Entity	1. Reporting entity: Greenbrook TMS Inc. (the “Company”), an Ontario corporation along with its subsidiaries, controls and operates a network of outpatient mental health services centers that specialize in the provision of Transcranial Magnetic Stimulation (“TMS”) therapy and other treatment modalities for the treatment of depression and related psychiatric services. The Company’s head and registered office is located at 890 Yonge Street, 7th Floor, Toronto, Ontario, Canada, M4W 3P4. The Company’s United States corporate headquarters is located at 8401 Greensboro Drive, Suite 425, Tysons Corner, Virginia, USA, 22102.

Basis of presentation

Basis of presentation	9 Months Ended
	Sep. 30, 2024
Basis of presentation	2. Basis of presentation: (a) Going concern: These condensed interim consolidated financial statements for the three and nine months ended September 30, 2024 have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) and the basis of presentation outlined in note 2(b) on the assumption that the Company is a going concern and will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business for the next 12 months. The Company has experienced losses since inception and has negative cash flow from operating activities of $36,809,738 for the nine months ended September 30, 2024 ($20,224,880 – nine months ended September 30, 2023). The Company’s cash balance, excluding restricted cash, as at September 30, 2024 was $368,512 ($3,323,708 as at December 31, 2023) and negative working capital as at September 30, 2024 was $17,818,245 (negative working capital of $17,681,089 as at December 31, 2023). On July 14, 2022, the Company entered into a credit agreement (the “Madryn Credit Agreement”), as amended, for a $75,000,000 secured credit facility (the “Madryn Credit Facility”) with Madryn Fund Administration, LLC and its affiliated entities (collectively, “Madryn”). Upon closing of the Madryn Credit Facility, the Company drew a $55,000,000 term loan under the Madryn Credit Facility. In addition, the Madryn Credit Facility permits the Company to draw up to an additional $20,000,000 in a single draw at any time on or prior to December 31, 2024 for purposes of funding future mergers and acquisition activity. On March 23, 2023, the Company completed a non-brokered On July 13, 2023, the Company entered into a purchase agreement (the “Alumni Purchase Agreement”) with Alumni Capital LP (“Alumni”). The Alumni Purchase Agreement provided equity line financing for sales from time to time of up to $4,458,156 of Common Shares. The Company issued an aggregate of 1,761,538 Common Shares under the Alumni Purchase Agreement for gross proceeds of $481,437. On February 26, 2024, the Company completed a registered direct offering of Common Shares (the “February 2024 Direct Offering”). Pursuant to the February 2024 Direct Offering, an aggregate of 2,828,249 Common Shares were issued at a price of $0.20 per Common Share, for aggregate gross proceeds to the Company of $565,649. See note 14. During the nine months ended September 30, 2024, the Company received an aggregate of $36,218,275 in debt financings from Madryn in order to satisfy short-term cash requirements, and certain amendments to the Madryn Credit Facility were also effected to amend the Company’s minimum liquidity covenant. See note 9. The terms of the Madryn Credit Facility require the Company to satisfy various financial covenants including a minimum liquidity and minimum consolidated revenue amounts that became effective on July 14, 2022 and September 30, 2022, respectively. A failure to comply with these covenants, or failure to obtain a waiver for any non-compliance, non-compliance December 9, 2024. In addition, the Company also received a waiver relating to the requirement to deliver financial statements within 90 days of each fiscal year end until April 26, 2024, and audited financial statements for such fiscal year, accompanied by a report and opinion of an independent certified public accountant which is not subject to any “going concern” or like qualification or exception or any qualification or exception as to the scope of such audit. As at September 30, 2024, the Company was in compliance with the financial covenants of the Madryn Credit Agreement, as amended. On October 3, 2024, October 15, 2024 and November 6, 2024, the Company received an aggregate of $5,106,599 in debt financing from Madryn in order to satisfy the Company’s short-term cash requirements. See note 25. On August 12, 2024, the Company entered into a definitive arrangement agreement (the “Arrangement Agreement”) with Neuronetics, Inc. (“Neuronetics”), in which Neuronetics will acquire all of the outstanding Common Shares of the Company in an all-stock As part of the Neuronetics Transaction, Madryn has agreed to convert all of the amount outstanding under the Madryn Credit Facility (as defined below) and all of the Subordinated Convertible Notes (as defined below) (including notes held by Madryn and other third-parties, which are forced to convert as a result of Madryn’s election) into Common Shares prior to the effective date of the Neuronetics Transaction. On December 10, 2024, the Neuronetics Transaction closing was announced with an effective date of December 9, 2024. See note 14 and note 25. On October 3, 2024, the Company converted all outstanding Subordinated Convertible Notes into an aggregate of 134,667,522 Common Shares at a conversion price of $0.078 per Common Share. See note 25. On February 22, 2024, the Company received the final delisting notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) due to the continued failure to satisfy either the $1.00 minimum bid price listing requirement in Nasdaq Listing Rule 5550(a)(2) or the minimum stockholders’ equity requirements in Nasdaq Listing Rule 5550(b). Consequently, the trading of the Company’s Common Shares was suspended as of the open of trading on February 26, 2024. The Company determined that it was in the overall best interests of the Company not to appeal the decision. Subsequently, the Company’s Common Shares have been quoted on OTCQB Market, operated by OTC Markets Group Inc. (the “OTCQB Market”). Although the Company believes it will become cash flow positive in the future, the timing of this is uncertain given that the Company has historically not been able to meet its forecast. The Company will require additional financing in order to fund its operating and investing activities in the future, including making timely payments to certain vendors, landlords, lenders and similar other business partners. The delay in such payments may result in potential defaults under the terms of the agreements the Company has with various parties. The Company has historically been able to obtain financing from supportive shareholders, its lenders and other sources when required and will be reliant on financing received from Neuronetics and other lenders; however, the Company may not be able to access further equity or debt financing when needed. As such, there can be no assurance that the Company will be able to obtain additional liquidity when needed or under acceptable terms, if at all. If additional financing is not obtained, the Company may not be able to repay its short-term obligations, which may result in a requirement to file for bankruptcy protection. The existence of the above-described conditions indicate substantial doubt as to the Company’s ability to continue as a going concern as at September 30, 2024. These condensed interim consolidated financial statements do not reflect adjustments that would be necessary if the going concern assumption was not appropriate. If the going concern basis was not appropriate for these condensed interim consolidated financial statements, then adjustments would be necessary to the carrying value of assets and liabilities, the reported expenses, and the condensed interim consolidated balance sheet classification used, and these adjustments may be material. (b) Basis of measurement: These condensed interim consolidated financial statements have been prepared on a historic cost basis except for financial instruments classified as fair value through profit or loss, which are stated at their fair value. Other measurement bases are described in the applicable notes. Presentation of the condensed interim consolidated balance sheet differentiates between current and non-current Regional operating loss presents regional operating loss on an entity-wide basis and is calculated as total revenue less direct center and patient care costs, other regional and center support costs, and depreciation. These costs encapsulate all costs (other than incentive compensation such as share-based compensation granted to senior regional employees) associated with the center and regional management infrastructure, including the cost of the delivery of treatments to patients and the cost of the Company’s regional patient acquisition strategy.
Pro Forma [Member]
Basis of presentation	2. Basis of Presentation The unaudited pro forma financial statements show the historical results of operations of Collegium and Ironshore and have been prepared to illustrate the effect of the Acquisition, including pro forma assumptions and adjustments related to the Acquisition, as described in these accompanying notes. The acquisition of Greenbrook is considered an acquisition of a business, as defined in Accounting Standards Codification (“ASC”) Topic 805, Business Combinations The unaudited pro forma condensed combined statements of operations are presented as if the Acquisition occurred on January 1, 2023. The historical consolidated financial information has been adjusted on a pro forma basis for transaction accounting adjustments as defined within Article 11 of Regulation S-X. The unaudited pro forma condensed combined financial information is provided for illustrative purposes only, and do not purport to represent what the actual consolidated results of the companies would have been had the Acquisition occurred on January 1, 2023, nor are they necessarily indicative of future consolidated results of operations of the Company. The pro forma condensed combined statement of operations neither reflect the costs of any integration activities nor the synergies and benefits that may result from realization of any operational efficiencies expected to result from the Acquisition of Greenbrook. The unaudited pro forma condensed combined balance sheet is presented as if the Acquisition occurred on September 30, 2024. The historical consolidated financial information has been adjusted on a pro forma basis for transaction accounting adjustments as defined within Article 11 of Regulation S-X. The unaudited pro forma balance sheet is provided for illustrative purposes only and does not purport to represent what the actual consolidated results of the companies would have been had the Acquisition occurred on September 30, 2024.

Significant accounting policies

Significant accounting policies	9 Months Ended
	Sep. 30, 2024
Material accounting policies
Significant accounting policies	3. Significant accounting policies: These condensed interim consolidated financial statements have been prepared using the material accounting policies consistent with those applied in the Company’s December 31, 2023 audited consolidated financial statements, except as described below relating to the application of ASC Topic 606, Revenue from Contracts with Customers (a) Revenue recognition: Other revenue is recognized at a point in time upon the performance of services under contracts with customers and represents the consideration to which the Company expects to be entitled. Other revenue includes revenue from research agreements. Research agreements consist of arrangements with other companies to perform studies and investigational tasks on the delivery and scalability of various treatment modalities. Revenue related to research agreements is recognized based on the completion of pre-set

Recent accounting pronouncement

Recent accounting pronouncements	9 Months Ended
	Sep. 30, 2024
Recent accounting pronouncements
Recent accounting pronouncements	4. Recent accounting pronouncements: Recent accounting pronouncements adopted: The Financial Accounting Standards Board (“FASB”) has issued the following amendments to the existing standards that became effective for periods beginning on or after January 1, 2024: (i) Accounting Standards Update 2023-09—Income The adoption of the amendments to the existing standards did not have a material impact on these condensed interim consolidated financial statements.

Property, plant and equipment

Property, plant and equipment	9 Months Ended
	Sep. 30, 2024
Property, plant and equipment
Property, plant and equipment	5. Property, plant and equipment: Leasehold TMS devices Total Cost Balance, December 31, 2023 $ 359,662 $ 6,427,908 $ 6,787,570 Additions —  699,903 699,903 Asset Disposal (8,950 ) (80,000 ) (88,950 ) Balance, September 30, 2024 $ 350,712 $ 7,047,811 $ 7,398,523 Accumulated depreciation Balance, December 31, 2023 $ 156,540 $ 1,837,051 $ 1,993,591 Depreciation 46,078 722,369 768,447 Asset Disposal (8,950 ) (80,000 ) (88,950 ) Balance, September 30, 2024 $ 193,668 $ 2,479,420 $ 2,673,088 Net book value Balance, December 31, 2023 $ 203,122 $ 4,590,857 $ 4,793,979 Balance, September 30, 2024 157,044 4,568,391 4,725,435

Intangible assets

Intangible assets	9 Months Ended
	Sep. 30, 2024
Intangible assets
Intangible assets	6. Intangible assets: Management Covenant not Total Cost Balance, December 31, 2023 $ 2,792,178 $ 355,238 $ 3,147,416 Additions —  —  —  Asset Disposal —  (355,238 ) (355,238 ) Balance, September 30, 2024 $ 2,792,178 $ —  $ 2,792,178 Accumulated amortization Balance, December 31, 2023 $ 2,176,641 $ 348,718 $ 2,525,359 Amortization 43,000 6,520 49,520 Asset Disposal —  (355,238 ) (355,238 ) Balance, September 30, 2024 $ 2,219,641 $ —  $ 2,219,641 Net book value Balance, December 31, 2023 $ 615,537 $ 6,520 $ 622,057 Balance, September 30, 2024 572,537 —  572,537

Right-of-use assets and lease l

Right-of-use assets and lease liabilities	9 Months Ended
	Sep. 30, 2024
Right-of-use assets and lease liabilities
Right-of-use assets and lease liabilities	7. Right-of-use The Company enters into lease agreements related to TMS devices and mental health treatment centers (“Treatment Centers”). These lease agreements range from one year to seven years in length. Right-of-use Lease liabilities have been measured by discounting future lease payments using a rate implicit in the lease or the Company’s incremental borrowing rate. The Company’s incremental borrowing rate during the period ended September 30, 2024 is 14.5% (December 31, 2023 – 14.5%). (a) Finance leases: Finance leases include lease agreements relating to TMS devices. September 30, Finance right-of-use $ 2,140,338 Impact of lease additions, disposals and/or modifications —  Exercise of buy-out (699,903 ) Depreciation on right-of-use (163,614 ) Finance right-of-use $ 1,276,821 September 30, Finance lease liabilities, beginning of the period $ 857,837 Impact of lease additions, disposals and/or modifications 10,601 Interest expense on lease liabilities 48,749 Payments of lease liabilities (541,492 ) Finance lease liabilities, end of the period $ 375,695 Less current portion of finance lease liabilities 355,161 Long term portion of finance lease liabilities $ 20,534 (b) Operating leases: Operating leases include lease agreements relating to Treatment Centers. September 30, Operating right-of-use $ 28,887,905 Impact of lease additions, disposals and/or modifications (2,125,346 ) Right-of-use (3,104,371 ) Operating right-of-use $ 23,658,188 September 30, Operating lease liabilities, beginning of the period $ 30,398,566 Impact of lease additions, disposals and/or modifications (2,180,550 ) Lease liability expense 2,389,817 Payments of lease liabilities (5,425,421 ) Operating lease liabilities, end of the period 25,182,412 Less current portion of operating lease liabilities 4,043,583 Long term portion of operating lease liabilities $ 21,138,829

Accounts payable and accrued li

Accounts payable and accrued liabilities	9 Months Ended
	Sep. 30, 2024
Accounts payable and accrued liabilities
Accounts payable and accrued liabilities	8. Accounts payable and accrued liabilities: The accounts payable and accrued liabilities are as follows: September 30, December 31, Accounts payable $ 10,563,496 $ 9,050,616 Accrued liabilities 4,385,207 4,651,014 Total $ 14,948,703 $ 13,701,630

Loans payable

Loans payable	9 Months Ended
	Sep. 30, 2024
Loans payable.
Loans payable	9. Loans payable: (a) Borrowings: TMS Credit Promissory Neuronetics Total Short Term $ 6,696 —  $ 7,412,790 $ 4,000,000 $ 11,419,486 Long Term —  131,595,084 178,981 —  131,774,065 Total, net $ 6,696 $ 131,595,084 $ 7,591,771 $ 4,000,000 $ 143,193,551 Unamortized capitalized financing costs —  2,907,505 151,081 —  3,058,586 Total, September 30, 2024 $ 6,696 $ 134,502,589 $ 7,742,852 $ 4,000,000 $ 146,252,137 (i) TMS Device loans: During the year ended December 31, 2022, the Company assumed loans as part of the Success TMS Acquisition (as defined below) from three separate financing companies for the purchase of TMS devices. These TMS device loans bear an average interest rate of 9.3% with average monthly blended interest and capital payments of $1,538 and matured or mature, as applicable, during the years ended or ending, as applicable, December 31, 2023 to December 31, 2025. There are no covenants associated with these loans. During the nine months ended September 30, 2024, the Company repaid TMS device loans totalling $52,265 (nine months ended September 30, 2023 – $122,010). (ii) Credit Facility: On July 14, 2022, the Company entered into the Madryn Credit Agreement in respect of the Madryn Credit Facility. The Madryn Credit Facility provided the Company with a $55,000,000 term loan (the “Existing Loan”) that was funded at closing on July 14, 2022, with an option to draw up to an additional $20,000,000 in a single draw at any time on or prior to December 31, 2024 for the purposes of funding future mergers and acquisition activity. As at December 31, 2022, all amounts borrowed under the Madryn Credit Facility bore interest at a rate equal to the three-month London Interbank Offered Rate (“LIBOR”) plus 9.0%, subject to a minimum three-month LIBOR floor of 1.5%. The Madryn Credit Facility matures over 63 months and provides for four years of interest-only payments. The initial principal balance of $55,000,000 is due in five equal 3 month installments beginning on September 30, 2026. The Company has granted general security over all assets of the Company in connection with the performance and prompt payment of all obligations of the Madryn Credit Facility. On February 1, February 21, March 20, March 24, August 1, September 15, October 19, November 2, November 15, December 5, December 14, and December 28, 2023, and January 19, February 5, February 15, March 1, March 15, March 29, April 15, May 1, May 15, June 4, June 25, June 27, July 18, August 2, August 19, September 5 and September 19, 2024, the Company entered into amendments to the Madryn Credit Facility, whereby Madryn extended an aggregate total of twenty-nine In addition, the Madryn Credit Facility was amended on February 21, 2023 to provide that, commencing March 31, 2023, all advances under the Madryn Credit Facility (including the New Loans) will cease to accrue interest using the LIBOR benchmark and instead will accrue interest at a rate equal to 9.0% plus the 3-month On September 19, 2024, the Madryn Credit Facility was amended to provide that the interest rate for any interest period occurring after September 19, 2024 shall be 0.0% per annum. The carrying amount of the Madryn Credit Facility as at September 30, 2024 is $131,595,084 (December 31, 2023 – $83,943,636). Interest expense for the three and nine months ended September 30, 2024 were $4,433,190 and $12,241,287, respectively (three and nine months ended September 30, 2023 – $2,542,545 and $7,169,931, respectively). Financing costs of $4,565,584 were incurred and are deferred over the term of the Madryn Credit Facility, of which $733,275 was incurred during the nine months ended September 30, 2024 associated with the various amendments. Amortization of deferred financing costs for the three and nine months ended September 30, 2024 were $270,981 and $705,889, respectively (three and nine months ended September 30, 2023 – $174,838 and $493,004, respectively) at an effective interest rate of 0.86% (December 31, 2023 – 1.01%) and were included in interest expense. In accordance with the terms of the Madryn Credit Agreement, the Company has issued conversion instruments (each, a “Madryn Conversion Instrument”) to Madryn and certain of its affiliated entities that provide the holders thereof with the option to convert up to $5,000,000 of the outstanding principal amount of the Madryn Credit Facility into Common Shares at a price per share equal to $1.90, subject to customary anti-dilution adjustments. The New Loans provide the holders with the option to convert up to $2,430,149 of the outstanding principal amount of the New Loans into Common Shares at a price per share equal to $1.90, subject to customary anti-dilution adjustments. The instrument is convertible into up to 3,910,604 Common Shares. The conversion instruments have been recorded utilizing the no proceeds allocated method, which results in all proceeds allocated to the financial liability. The terms of the Madryn Credit Agreement require the Company to satisfy various affirmative and negative covenants and to meet certain financial tests, including but not limited to, consolidated minimum revenue and minimum liquidity covenants. In addition, the Madryn Credit Agreement contains affirmative and negative covenants that limit, among other things, the Company’s ability to incur additional indebtedness outside of what is permitted under the Madryn Credit Agreement, create certain liens on assets, declare dividends and engage in certain types of transactions. The Madryn Credit Agreement also includes customary events of default, including payment and covenant breaches, bankruptcy events and the occurrence of a change of control. The Madryn Credit Facility also requires the Company to deliver to Madryn annual audited financial statements that do not contain any “going concern” note, however, the Company has obtained waivers from Madryn with respect to such obligation for fiscal 2023. On June 14, 2023, the Company received a waiver from Madryn under the Madryn Credit Agreement to temporarily reduce the Company’s minimum liquidity covenant until June 30, 2023. As consideration for the waiver, Madryn received an amendment fee in the amount of $1,000,000, which was paid-in-kind paid-in-kind paid-in-kind On February 21, March 20, June 14, July 3, July 14, August 1, August 14, September 15, September 29, October 12, November 15 and December 14, 2023, and January 19, February 15, March 15, March 28, May 1, June 4, June 25, July 18, August 2, September 5, October 3, October 15, November 6 and November 27, 2024, the Company received waivers from Madryn with respect to the Company’s non-compliance Pursuant to the 2023 Private Placement completed on March 23, 2023, Madryn is also a shareholder of the Company. Pursuant to the Arrangement Agreement entered into on August 12, 2024, Madryn has agreed to convert all of the amount outstanding under the Madryn Credit Facility into Common Shares, prior to the effective date of the Neuronetics Transaction. See note 14 and note 25 (iii) Promissory notes: On July 14, 2022, the Company assumed two promissory notes in connection with the acquisition of Check Five LLC, a Delaware limited liability company (doing business as “Success TMS”) (the “Success TMS Acquisition”) totaling $200,000. These promissory notes bear interest at a rate of 5% per annum and have a maturity date of December 31, 2025. Upon acquisition, these two promissory notes were fair valued using an interest rate of 12%. On February 3, 2023, the Company issued additional promissory notes to certain officers of the Company, in the aggregate amount of $60,000. These promissory notes, along with the $690,000 issued to shareholders (see note 10(b)) on February 3, 2023, total $750,000 (the “February 2023 Notes”). The February 2023 Notes bear interest at a rate consistent with the Madryn Credit Facility and mature on the earlier of September 30, 2027, at the election of the noteholders upon a change of control, upon the occurrence of an event of default and acceleration by the noteholders, or the date on which the loans under the Madryn Credit Facility are repaid. On August 28, 2023, the total $60,000 par value of the February 2023 Notes issued to certain officers of the Company were subsequently exchanged for Subordinated Convertible Notes. On August 15, August 28, September 1, September 25, September 26, September 27, September 29, October 3, October 12 and October 13, 2023, the Company issued subordinated convertible promissory notes (the “Subordinated Convertible Notes”) to Madryn, certain officers of the Company and various investors in an aggregate amount of $6,505,000 pursuant to a note purchase agreement (as amended or supplemented from time to time, the “Note Purchase Agreement”). All Subordinated Convertible Notes bear interest at a rate consistent with the Madryn Credit Facility and mature on the earlier of March 31, 2028, in the event of a change of control, acceleration of other indebtedness, or six months following repayment or refinancing of all loans under the Madryn Credit Facility. In accordance with the terms of the Note Purchase Agreement, each holder of a Subordinated Convertible Note has the option to convert any amount up to the outstanding principal amount plus accrued interest into Common Shares at any time at the election of the holders of the Subordinated Convertible Notes or on a mandatory basis by all noteholders at the request of Madryn. The Subordinated Convertible Notes are convertible into Common Shares at a conversion price equal to the lesser of 85% of the closing price per Common Share on Nasdaq or any other market as of the closing date for such Subordinated Convertible Note, as adjusted from time to time, 85% of the 30-day In connection with the issuance of the Subordinated Convertible Notes, the Company concurrently entered into amendments to the Madryn Credit Agreement and the Neuronetics Note (as defined below), pursuant to which the Company is permitted to incur the indebtedness under the Subordinated Convertible Notes. Financing costs of $184,755 were incurred and are deferred over the term of the Subordinated Convertible Notes. Amortization of deferred financing costs for the three and nine months ended September 30, 2024 was $8,160 and $23,331, respectively (three and nine months ended September 30, 2023 – $10,034 and $10,034, respectively) and were included in interest expense. The carrying value of all promissory notes referenced in note 9(a)(iii) as at September 30, 2024 is $7,591,771 (December 31, 2023 – $6,796,861). Interest expense for the three and nine months ended September 30, 2024 was $272,687 and $794,911, respectively (three and nine months ended September 30, 2023 – $56,354 and $70,107, respectively). During the three and nine months ended September 30, 2024, the Company repaid promissory notes totalling nil and nil, respectively (three and nine months ended September 30, 2023 – nil and nil, respectively). On October 3, 2024, all outstanding Subordinated Convertible Notes were converted into an aggregate of 134,667,522 Common Shares at a conversion price of $0.078 per Common Share, following the receipt of a conversion notice from Madryn. As part of the conversion, all interest accrued on the Subordinated Convertible Notes held by Madryn was waived. As at September 30, 2024, the total amount outstanding under the Subordinated Convertible Notes is recognized as a current liability due to the conversion on October 3, 2024. See note 14 and note 25. (iv) Neuronetics Note: On March 31, 2023, the Company entered into an agreement with Neuronetics to convert the Company’s outstanding account balance payable to Neuronetics of $5,883,644, together with Neuronetics’ out-of-pocket Pursuant to the terms of the Neuronetics Note, in the event of default under the Neuronetics Note, the Company will be required to issue common share purchase warrants (the “Neuronetics Warrants”) to Neuronetics equal to (i) 200% of the unpaid amount of any delinquent amount or payment due and payable under the Neuronetics Note, together with all outstanding and unpaid accrued interest, fees, charges and costs, divided by (ii) the exercise price of the Neuronetics Warrants, which will represent a 20% discount to the 30-day In connection with the entry into the Neuronetics Note, the Company concurrently entered into an amendment to the Madryn Credit Agreement pursuant to which the Company is permitted to incur the indebtedness under the Neuronetics Note. The carrying value of the Neuronetics Note as at September 30, 2024 is $4,000,000 (December 31, 2023 – $5,200,000). Interest expense for the three and nine months ended September 30, 2024 was $137,372 and $451,907, respectively (three and nine months ended September 30, 2023 – $188,889 and $378,964, respectively). During the three and nine months ended September 30, 2024, the Company repaid a total of $537,372 and $1,651,907, respectively of the Neuronetics Note (three and nine months ended September 30, 2023 – $533,333 and $533,333, respectively). On August 12, 2024, the Company entered into the Arrangement Agreement with Neuronetics, pursuant to which Neuronetics will acquire all of the outstanding Common Shares of the Company in an all-stock (b) Non-controlling September 30, December 31, Non-controlling $ 58,074 $ 63,174 The non-controlling

Shareholder loans

Shareholder loans	9 Months Ended
	Sep. 30, 2024
Shareholder loans
Shareholder loans	10. Shareholder loans: (a) February 2023 Notes, February 2023 Greybrook Note and August 2023 Greybrook Note: On February 3, 2023, the Company issued the February 2023 Notes to certain shareholders of the Company in an aggregate amount of $690,000. The February 2023 Notes bear interest at a rate consistent with the Madryn Credit Facility and mature on the earlier of September 30, 2027, at the election of the noteholders upon a change of control, upon the occurrence of an event of default and acceleration by the noteholders, or the date on which the loans under the Madryn Credit Facility are repaid. On February 28, 2023, the Company issued a promissory note to Greybrook Health, who is a significant shareholder of the Company (the “February 2023 Greybrook Note”). The February 2023 Greybrook Note totals $1,000,000 and bears interest at a rate consistent with the Madryn Credit Facility and matures on the earlier of September 30, 2027, at the election of the noteholder upon a change of control, upon the occurrence of an event of default and acceleration by the noteholder, or the date on which the loans under the Madryn Credit Facility are repaid. In conjunction with the issuance of the February 2023 Greybrook Note, the Company granted Greybrook Health an option to convert up to $1,000,000 of the outstanding principal amount of the February 2023 Greybrook Note into Common Shares at a conversion price per share equal to 85.0% of the volume-weighted average trading price of the Common Shares on the Nasdaq for the five trading days immediately preceding the date of conversion, subject to customary anti-dilution adjustments and conversion limitations required by Nasdaq. The conversion instruments have been recorded utilizing the no proceeds allocated method, which results in all proceeds allocated to the financial liability. This conversion instrument was terminated on August 28, 2023 in connection with the exchange of the February 2023 Greybrook Note into Subordinated Convertible Notes. As additional consideration for the February 2023 Greybrook Note, the Company issued 135,870 common share purchase warrants to Greybrook Health (the “February 2023 Greybrook Warrants”), each exercisable for one Common Share at an exercise price of $1.84 per Common Share, subject to customary anti-dilution adjustments, expiring on February 28, 2028. There is a cashless exercise feature associated with the February 2023 Greybrook Warrants available to Greybrook Health. On February 28, 2023, the fair value of the February 2023 Greybrook Warrants at grant date was $63,587. Per ASC 815, the February 2023 Greybrook Warrants meet the applicable criteria to qualify for equity classification. The warrants are initially recognized according to their relative fair value as compared to the host financial liability. The relative fair value of the February 2023 Greybrook Warrants on the date of inception has been deducted from the carrying value of the February 2023 Greybrook Note as a financing cost. See note 15(b). On August 1, 2023, the Company issued an additional promissory note to Greybrook Health (the “August 2023 Greybrook Note”). The August 2023 Greybrook Note totals $1,000,000 and bears interest at a rate consistent with the Madryn Credit Facility and matures on the earlier of September 30, 2027, at the election of the noteholder upon a change of control, upon the occurrence of an event of default and acceleration by the noteholder, or the date on which the loans under the Madryn Credit Facility are repaid. In conjunction with the issuance of the August 2023 Greybrook Note, the Company granted Greybrook Health 250,000 common share purchase warrants, exercisable at 85% of the volume weighted average trading price of the Common Shares on the Nasdaq for the five trading days immediately preceding the exercise date, or if the Common Shares are not listed on any trading market at the time of exercise, a per share price based on fair market value, as determined by the board of directors of the Company (the “Board”), subject to customary anti-dilution adjustments, expiring on August 1, 2028 (the “August 2023 Greybrook Warrants” and, together with the February 2023 Greybrook Warrants, the “Greybrook Warrants”). See note 15(b). On August 1, 2023, the fair value of the August 2023 Greybrook Warrants at grant date was $19,728. Per ASC 815, the August 2023 Greybrook Warrants meet the applicable criteria to qualify for equity classification. The warrants are initially recognized according to their relative fair value as compared to the host financial liability. The relative fair value of the August 2023 Greybrook Warrants on the date of inception has been deducted from the carrying value of the August 2023 Greybrook Note as a financing cost. See note 15(b). Financing costs of $109,132 were incurred and are deferred over the term of the February 2023 Notes, the February 2023 Greybrook Note and the August 2023 Greybrook Note. Amortization of deferred financing costs and deferred losses for the three and nine months ended September 30, 2024 were nil and nil, respectively (three and nine months ended September 30, 2023 – $3,982 and $7,656, respectively) and were included in interest expense. On August 28, 2023, the February 2023 Notes, February 2023 Greybrook Note and August 2023 Greybrook Note were exchanged into Subordinated Convertible Notes. All unamortized financing costs and deferred losses were immediately expensed and interest accrued was forfeited upon exchange. A gain of $39,822 on loan extinguishment was recognized in equity in contributed surplus for the extinguishment of the February 2023 Notes, February 2023 Greybrook Note and August 2023 Greybrook Note as they resulted from a transaction with the owners in their capacity as the owners. The carrying value of the February 2023 Notes, the February 2023 Greybrook Note and the August 2023 Greybrook Note as at September 30, 2024 is nil (December 31, 2023 – nil). Interest expense for the three and nine months ended September 30, 2024 were nil and nil, respectively (three and nine months ended September 30, 2023 – $160,940 and $377,088, respectively). (b) Subordinated Convertible Notes: On August 15, 2023, the Company issued Subordinated Convertible Notes to certain shareholders of the Company in an aggregate amount of $500,000, and on August 28, 2023, exchanged $3,690,000 of the February 2023 Notes, the February 2023 Greybrook Note and the August 2023 Greybrook Note for Subordinated Convertible Notes. The Subordinated Convertible Notes bear interest at a rate consistent with the Madryn Credit Facility, are convertible into Common Shares pursuant to the terms of the Note Purchase Agreement and mature on the earlier of March 31, 2028, in the event of a change of control, acceleration of other indebtedness, or six months following repayment or refinancing of all loans under the Madryn Credit Facility. The conversion feature associated with the Subordinated Convertible Notes have been recorded utilizing the no proceeds allocated method, which results in all proceeds allocated to the financial liability. In connection with the issuance of the Subordinated Convertible Notes, the Company concurrently entered into amendments to the Madryn Credit Agreement and the Neuronetics Note, pursuant to which the Company is permitted to incur the indebtedness under the Subordinated Convertible Notes. Financing costs of $42,105 were incurred and are deferred over the term of the Subordinated Convertible Notes. Amortization of deferred financing costs for the three and nine months ended September 30, 2024 were $1,860 and $5,321, respectively (three and nine months ended September 30, 2023 – $803 and $803, respectively) and were included in interest expense. The carrying value of the Subordinated Convertible Notes as at September 30, 2024 is $3,690,568 (December 31, 2023 – $3,312,641). Interest expense for the three and nine months ended September 30, 2024 were $129,600 and $377,927, respectively (three and nine months ended September 30, 2023 – $44,282 and $44,282, respectively). During the three and nine months ended September 30, 2024, the Company repaid nil and nil of the Subordinated Convertible Notes, respectively (three and nine months ended September 30, 2023 – nil and nil, respectively). On October 3, 2024, all outstanding Subordinated Convertible Notes were converted into an aggregate of 134,667,522 Common Shares at a conversion price of $0.078 per Common Share, following the receipt of a conversion notice from Madryn. As at September 30, 2024, the total amount outstanding under the Subordinated Convertible Notes is recognized as a current liability due to the conversion on October 3, 2024. See note 14 and note 25.

Other payables

Other payables	9 Months Ended
	Sep. 30, 2024
Other Liabilities Disclosure [Abstract]
Other payables	11. Other payables: (a) Lender warrants: September 30, December 31, Lender warrants $ —  $ —  On December 31, 2020, as consideration for providing a credit and security agreement (the “Oxford Credit Facility”), the Company issued 51,307 common share purchase warrants to Oxford Finance LLC, each exercisable for one Common Share at an exercise price of C$11.20 per Common Share, expiring on December 31, 2025 (the “Oxford Warrants”). As the exercise price is denoted in a different currency than the Company’s functional currency, the Oxford Warrants are recorded as a financial liability on the condensed interim consolidated balance sheets. As at September 30, 2024, the value of the Oxford Warrants was nil nil The change in fair value of the Oxford Warrants during the three and nine months ended September 30, 2024 was nil and nil, respectively (three and nine months ended September 30, 2023 – decrease of nil and $6,567, respectively) and was recorded in corporate, general and administrative expenses. Under the terms of the Arrangement Agreement, each Oxford Warrant (whether vested or unvested) outstanding immediately prior to the closing time of the Neuronetics Transaction (the “Effective Time”) will be, and will be deemed to be, surrendered for cancellation and transferred to the Company in consideration for the issuance by the Company of that number of Common Shares (‘‘Net Warrant Surrender Shares’’), if any, equal to, rounded down to the nearest whole share: (i) the number of Common Shares subject to such Oxford Warrant immediately prior to the Effective Time minus (ii) the number of Common Shares that, when multiplied by the closing price of a Common Share on the OTCQB Market on the trading day immediately preceding the Effective Time, is equal to the aggregate exercise price of such Oxford Warrant (and in the event that such number of Common Shares is negative, it will be deemed to be zero), and the holder of the Oxford Warrant will be and will be deemed to be the holder of such number of Net Warrant Surrender Shares. (b) Deferred share units: September 30, December 31, Deferred share units $ 43,460 $ 376,565 On May 6, 2021, the Company adopted a deferred share unit plan (the “DSU Plan”) for non-employee “Non-Employee Non-Employee Non-Employee Following a Non-Employee Non-Employee Non-Employee ten Non-Employee As the DSUs are cash-settled, the DSUs are recorded as cash-settled share-based payments and a financial liability has been recognized on the condensed interim consolidated balance sheets. During the three and nine months ended September 30, 2024, nil and 2,588,746 DSUs were granted, respectively (three and nine months ended September 30, 2023 – 469,384 and 874,601, respectively). As at September 30, 2024, the value of the financial liability attributable to the DSUs was $43,460 (December 31, 2023 – $376,565). For the three and nine months ended September 30, 2024, the Company recognized a recovery of $306,856 and $333,105, respectively (three and nine months ended September 30, 2023 – recovery of $151,084 and $273,938, respectively) in corporate, general and administrative expenses related to the DSUs. In accordance with the Arrangement Agreement, each DSU, whether vested or unvested, outstanding immediately prior to the Effective Time will be deemed to be unconditionally fully vested, and thereafter such DSU will, without any further action by or on behalf of the holder of such DSU, be deemed to be assigned and transferred by such holder to the Company and will immediately be cancelled in exchange for: (i) if the closing price of a Common Share on the OTCQB Market on the trading day immediately preceding the Effective Time (the “Effective Date Market Price”’) is less than or equal to $0.0846 (the ‘‘Minimum Price’’), a cash payment equal to the Effective Date Market Price; and (ii) if the Effective Date Market Price is greater than the Minimum Price, at the election of Neuronetics, either (A) a cash payment equal to the Effective Date Market Price, or (B) such number of shares of common stock of Neuronetics (“Neuronetics Shares”) equal to the Effective Date Market Price divided by the closing price of a Neuronetics Share on Nasdaq on the trading day immediately preceding the Effective Date, less any applicable withholdings. (c) Performance share units: September 30, December 31, Performance share units $ —  $ 1,047 On May 6, 2021, the Company’s Equity Incentive Plan was amended and restated to permit the Company to grant performance share units (“PSUs”) and restricted share units (“RSUs”), in addition to stock options. Under the Equity Incentive Plan, the Company pays equity instruments of the Company, or a cash payment equal to the fair market value thereof, as consideration in exchange for employee and similar services provided to the Company. The Equity Incentive Plan is open to employees, directors, officers and consultants of the Company and its affiliates; however, Non-Employee On August 5, 2021, 38,647 PSUs were granted under the Equity Incentive Plan. The performance period in respect of this award was August 5, 2021 to December 31, 2023. The PSUs vested on December 31, 2023 (the “Vesting Date”). Pursuant to the grant agreement, upon satisfaction of the performance vesting conditions, the PSUs were settled in cash. The Company finalized that 3,865 PSUs vested on the Vesting Date. As at September 30, 2024, the value of the financial liability attributable to the PSUs is nil (December 31, 2023 – $1,047). As at September 30, 2024, the Company has not issued any RSUs under the Equity Incentive Plan (December 31, 2023 – nil). The change in fair value of the PSUs during the three and nine months ended September 30, 2024 was a decrease of nil and $1,047, respectively (three and nine months ended September 30, 2023 – a decrease of $1,507 and $43,748, respectively) and was recorded in corporate, general and administrative expenses. (d) Device contract termination: September 30, December 31, Device contract termination $ —  $ 3,750,000 On August 21, 2023, the Company entered into a settlement and mutual release agreement with a TMS device manufacturer for the termination of TMS device contracts. In accordance with the terms of the settlement, the Company recognized an amount payable of $6,600,000, due in equal instalments over 44 weeks. As a result of the settlement and mutual release agreement, the Company recognised a gain on extinguishment of liabilities totalling $2,030,635, offset by a loss on impairment of right-of-use (e) Klein Note settlement: September 30, December 31, Klein Note settlement $ —  $ 1,603,169 On July 14, 2022, in connection with the Success TMS Acquisition, the Company assumed the obligation of Success TMS to repay a promissory note (the “Klein Note”) to Benjamin Klein, who was a significant shareholder of the Company, totalling $2,090,264. On November 20, 2023, the Company entered into a settlement agreement in respect of the Klein Note. In accordance with the terms of the settlement, the Company was required to make payments totalling $2,228,169, structured as an initial immediate payment of $250,000, weekly payments of $75,000 thereafter up to and until the May 1, 2024 maturity date of the promissory note, upon which the balance owing became due. In accordance with the terms of the settlement, the Klein Note was fully repaid on May 1, 2024. (f) PA Settlement Agreement: September 30, December 31, PA Settlement Agreement $ 533,333 $ —  On May 24, 2023, Success TMS and its direct and indirect owners, including Benjamin Klein filed a complaint in the Superior Court of the State of Delaware against the Company and certain executive officers of the Company, and subsequently filed a first amended complaint on August 31, 2023 (the “Delaware Complaint”), concerning alleged disputes arising out of the Success TMS Acquisition. On August 9, 2024, the Company entered into a settlement agreement and release (the “PA Settlement Agreement”) with Benjamin Klein, Success Behavioral Holdings, LLC, Theragroup LLC, Batya Klein (collectively, the “Plaintiffs”) and The Bereke Trust U/T/A dated 2/10/03 to fully settle the Delaware Complaint (the “Settlement”). Pursuant to the PA Settlement Agreement and in full satisfaction of the claims, the Company has agreed to (i) pay the Plaintiffs a cash settlement amount equal to $800,000, comprised of a $200,000 up-front In conjunction with the Settlement, Benjamin Klein relinquished to the Company all of the 11,634,660 Common Shares (the “Klein Shares”) beneficially owned, controlled or directed, directly or indirectly, by Benjamin Klein that were issued in connection with the Success TMS Acquisition in July 2022 (which includes 2,908,665 Common Shares that were held in escrow and were released back to the Company). The Klein Shares were returned to treasury for cancellation. (g) Neuronetics Transaction Costs: September 30, December 31, Neuronetics Transaction Costs $ 1,370,602 $ —  It has been agreed between the parties to the Arrangement Agreement that certain transaction costs incurred by the Company in connection with the Neuronetics Transaction (the “Neuronetics Transaction Costs”) will be assumed and paid by Neuronetics on closing of the Neuronetics Transaction. The Neuronetics Transaction Costs include, without limitation, fees and expenses of financial advisors, any amount paid to current or purported finders, advisors or dealers, legal advisors, auditors, or other professional consultants, and printing, mailing, transfer agent and depositary and other costs and expenses relating to the special meeting of the Company’s shareholders, required to be called and held in accordance with the Arrangement Agreement. See note 14. As of September 30, 2024, the Neuronetics Transaction Costs were $1,370,602 (December 31, 2023 – nil).

Deferred and contingent conside

Deferred and contingent consideration	9 Months Ended
	Sep. 30, 2024
Deferred and contingent consideration
Deferred and contingent consideration	12. Deferred and contingent consideration: September 30, December 31, Deferred and contingent consideration $ 1,000,000 $ 1,000,000 The deferred and contingent consideration payable balance related to the acquisition of Achieve TMS East, LLC and Achieve TMS Central, LLC (the “Achieve TMS East/Central Acquisition”) as at December 31, 2021 was $1,250,000, made up of an estimated nil earn-out As at September 30, 2024, the deferred and contingent consideration in relation to the Achieve TMS East/Central Acquisition was $1,000,000 (December 31, 2023 – $1,000,000).

Advance for research collaborat

Advance for research collaboration	9 Months Ended
	Sep. 30, 2024
Advance for research collaboration.
Advance for research collaboration	13. Advance for research collaboration: September 30, December 31, Advance for research collaboration $ —  $ 1,300,000 On December 29, 2023, the Company entered into a three-year The research collaboration agreement outlines a payout to the Company of $3,000,000 upon the completion of various milestones, with $1,300,000 received on signing. For the three and nine months ended September 30, 2024, the Company has recognized $200,000 and $1,500,000, respectively, in other revenue on the condensed interim consolidated statement of comprehensive loss (three and nine months ended September 30, 2023 – nil and nil, respectively). As at September 30, 2024, the Company has recorded nil in advance for research collaboration on the condensed interim consolidated balance sheet (December 31, 2023 – $1,300,000).

Common shares

Common shares	9 Months Ended
	Sep. 30, 2024
Common shares
Common shares	14. Common shares: The Company is authorized to issue an unlimited number of Common Shares and an unlimited number of preferred shares, issuable in series. As at September 30, 2024 and December 31, 2023, there were nil preferred shares issued and outstanding. Number Total December 31, 2023 42,774,011 $ 120,741,061 Issuance of Common Shares – February 2024 Direct Offering 2,828,249 495,649 Surrender and Cancellation of Common Shares – PA Settlement Agreement (11,634,660 ) —  September 30, 2024 33,967,600 $ 121,236,710 (a) February 2024 Direct Offering: On February 26, 2024, the Company completed the February 2024 Direct Offering. Pursuant to the February 2024 Direct Offering, an aggregate of 2,828,249 Common Shares were issued at a price of $0.20 per Common Share, for aggregate gross proceeds to the Company of $565,649. The Company incurred financing costs of $70,000 which was recorded as a reduction in equity. (b) PA Settlement Agreement: On August 9, 2024, the Company entered into the PA Settlement Agreement. In conjunction with the PA Settlement Agreement, on August 15, 2024, Benjamin Klein relinquished to the Company all of the 11,634,660 Klein Shares that were issued in connection with the Success TMS Acquisition in July 2022. See note 11. (c) Arrangement Agreement: On August 12, 2024, the Company entered into the Arrangement Agreement with Neuronetics, in which Neuronetics will acquire all of the outstanding Common Shares of the Company in the Neuronetics Transaction. The Board of Directors of each of the Company and Neuronetics have unanimously approved the Neuronetics Transaction. Under the terms of the Arrangement Agreement, the Company’s shareholders will receive a fraction of a share of Neuronetics common stock (each whole share of Neuronetics common stock, a “Neuronetics Share”) for each Common Share owned at the exchange ratio described below such that immediately following the closing of the Neuronetics Transaction, Neuronetics shareholders will own approximately 57% of the combined company, and the Company’s shareholders will own approximately 43% of the combined company, respectively, on a fully diluted basis. As of the date of the Arrangement Agreement, each Common Share is expected to be exchanged for 0.01149 Neuronetics Shares at the closing of the Neuronetics Transaction, subject to adjustment for any interim period funding by Madryn and other customary adjustments prior to the closing based on the terms of the Arrangement Agreement (the “Exchange Ratio”). An aggregate of 25,304,971 Neuronetics Shares will be issued to the Company’s shareholders in connection with the Neuronetics Transaction. The Neuronetics Transaction will be implemented by way of a court-approved plan of arrangement under the Business Corporations Act (Ontario). The Neuronetics Transaction will be implemented by way of a court-approved plan of arrangement under the Business Corporations Act As part of the Neuronetics Transaction, Madryn has agreed to convert all of the amount outstanding under the Madryn Credit Facility and all of the Subordinated Convertible Notes (including notes held by Madryn and other third-parties, which are forced to convert as a result of Madryn’s election) into Common Shares prior to the effective date of the Neuronetics Transaction. As a result, subject to adjustment for any interim period funding by Madryn and other customary adjustments, Madryn will own 95.3% of the Common Shares immediately prior to closing and will receive 95.3% of the Neuronetics Shares being issued to the Company’s shareholders. See note 25. The Neuronetics Transaction requires approval by (i) at least 66 2/3 61-101 Protection of Minority Security Holders in Special Transactions 61-101”) The Arrangement Agreement provides for mutual termination fees of $1,900,000 in the event the Neuronetics Transaction is terminated by either party in certain circumstances, including to enter into a superior proposal. The combined company will continue to operate as Neuronetics, Inc., and trade under the ticker STIM on Nasdaq. In connection with closing of the Neuronetics Transaction, Neuronetics intends to cause the Common Shares to be delisted from the OTCQB Market and to cause the Company to submit an application to cease to be a reporting issuer under applicable Canadian securities laws. Each of Neuronetics’ directors and certain members of the executive leadership team, as of August 12, 2024, who hold in the aggregate 1,680,718 Neuronetics Shares (representing approximately 5.55% of issued and outstanding Neuronetics Shares (on a fully-diluted basis)) have entered into voting support agreements agreeing to vote their stock in favor of the issuance of Neuronetics Shares in connection with the Neuronetics Transaction at a special meeting of Neuronetics stockholders (the “Neuronetics Meeting”) called for November 8, 2024 for such purpose. The Neuronetics Meeting was held on November 8, 2024. See note 25. Key shareholders of the Company, including Madryn, Greybrook Health and 1315 Capital, and directors and certain members of the executive leadership team (collectively, the Greenbrook Locked-Up non-diluted Locked-Up non-diluted 61-101. The Madryn voting agreement is terminable under certain specified circumstances including in the event of receipt of a superior proposal that satisfies a hurdle that represents a 20% premium to the value of the consideration payable under the Neuronetics Transaction and, concurrently therewith, the Arrangement Agreement is terminated for a superior proposal upon payment of a termination fee. The voting agreements entered into with other key shareholders of the Company are terminable under certain specified circumstances, including upon the termination of the Madryn voting agreement. On December 10, 2024, the Neuronetics Transaction closing was announced. See note 25.

Contributed surplus

Contributed surplus	9 Months Ended
	Sep. 30, 2024
Contributed surplus
Contributed surplus	15. Contributed surplus: Contributed surplus is comprised of share-based compensation and lender warrants. (a) Share-based compensation - stock options Stock options granted under the Equity Incentive Plan are equity-settled. The fair value of the grant of the options is recognized as an expense in the condensed interim consolidated statements of comprehensive loss. The total amount to be expensed is determined by the fair value of the options granted. The total expense is recognized over the vesting period which is the period over which all of the service vesting conditions are satisfied. The vesting period is determined at the discretion of the Board and has ranged from immediate vesting to over three years. The maximum number of Common Shares reserved for issuance, in the aggregate, under the Equity Incentive Plan is 10% of the aggregate number of Common Shares outstanding, provided that the maximum number of RSUs and PSUs shall not exceed 5% of the aggregate number of Common Shares outstanding. As at September 30, 2024, this represented 3,396,760 Common Shares (December 31, 2023 – 4,277,401). As at September 30, 2024, 2,219,500 stock options are outstanding (December 31, 2023 – 1,704,500). The stock options have an expiry date of ten years from the applicable date of issue. The Company has not issued any RSUs or equity-settled PSUs under the Equity Incentive Plan. September 30, 2024 December 31, 2023 Number of Weighted Number of Weighted Outstanding, beginning of period 1,704,500 $ 3.11 764,667 $ 8.15 Granted 575,000 0.10 1,313,000 0.63 Forfeited (55,000 ) (0.75 ) (373,167 ) (4.71 ) Expired (5,000 ) (0.75 ) —  —  Outstanding, end of period 2,219,500 $ 2.39 1,704,500 $ 3.11 The weighted average contractual life of the outstanding options as at September 30, 2024 was 7.71 years (December 31, 2023 – 7.89 years). The total number of stock options exercisable as at September 30, 2024 was 1,277,749 (December 31, 2023 – 1,087,164). During the three and nine months ended September 30, 2024, the Company recorded a total share-based compensation expense in respect of stock options of $51,923 and $111,110, respectively (three and nine months ended September 30, 2023 – $14,740 and $591,470, respectively). As at September 30, 2024, the total compensation cost not yet recognized related to options granted is approximately $86,166 (December 31, 2023 – $183,312) and will be recognized over the remaining average vesting period of 1.10 years (December 31, 2023 – 1.03 years). Under the terms of the Arrangement Agreement, each option (whether vested or unvested) outstanding immediately prior to the Effective Time will be, and will be deemed to be, surrendered for cancellation and transferred to the Company in consideration for the issuance by the Company of that number of Net Option Surrender Shares, if any, equal to, rounded down to the nearest whole share: (i) the number of Common Shares subject to such option immediately prior to the Effective Time minus (ii) the number of Common Shares that, when multiplied by the closing price of a Common Share on the OTCQB Market on the trading day immediately preceding the Effective Time, is equal to the aggregate exercise price of such option (and in the event that such number of Common Shares is negative, it will be deemed to be zero), and the holder of the option will be and will be deemed to be the holder of such number of Net Option Surrender Shares. (b) Greybrook Warrants As consideration for the purchase of the February 2023 Greybrook Note, the Company issued 135,870 February 2023 Greybrook Warrants to Greybrook Health. Each February 2023 Greybrook Warrant is exercisable for one Common Share at an exercise price of $1.84, subject to customary anti-dilution adjustments. The February 2023 Greybrook Warrants will expire on February 28, 2028. Per ASC 815, the February 2023 Greybrook Warrants meet the applicable criteria to qualify for equity classification and therefore are included in contributed surplus. See note 10(a). The fair value of the February 2023 Greybrook Warrants granted on February 28, 2023 was estimated to be $0.47 per warrant using the Black-Scholes option pricing model based on the following assumptions: volatility of 48.86% calculated based on a comparable company; remaining life of 5.0 years; expected dividend yield of 0%; forfeiture rate of 0% and an annual risk-free interest rate of 4.18%. As consideration for the purchase of the August 2023 Greybrook Note issued on August 1, 2023, the Company issued 250,000 August 2023 Greybrook Warrants. Each August 2023 Greybrook Warrant is exercisable for one Common Share at an exercise price equal to 85% of the volume weighted average trading price of the Common Shares on the Nasdaq for the five trading days Under the terms of the Arrangement Agreement, each Greybrook Warrant (whether vested or unvested) outstanding immediately prior to the Effective Time will be, and will be deemed to be, surrendered for cancellation and transferred to the Company in consideration for the issuance by the Company of that number of Common Shares (‘‘Net Warrant Surrender Shares’’), if any, equal to, rounded down to the nearest whole share: (i) the number of Common Shares subject to such Greybrook Warrant immediately prior to the Effective Time minus (ii) the number of Common Shares that, when multiplied by the closing price of a Common Share on the OTCQB Market on the trading day immediately preceding the Effective Time, is equal to the aggregate exercise price of such Greybrook Warrant (and in the event that such number of Common Shares is negative, it will be deemed to be zero), and the holder of the Greybrook Warrant will be and will be deemed to be the holder of such number of Net Warrant Surrender Shares. The fair value of the August 2023 Greybrook Warrants granted on August 1, 2023 were valued at $19,728 using a closing share price of $0.50 per share and 85% of the volume weighted average trading price of the Common Shares five trading days The weighted average contractual life of the Greybrook Warrants as at September 30, 2024 was 3.7 years (December 31, 2023 – 4.4 years). The total number of Greybrook Warrants exercisable as at September 30, 2024 was 385,870 (December 31, 2023 – 385,870).

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2024
Contingencies
Contingencies	16. Contingencies: The Company may be involved in certain legal matters arising from time to time in the normal course of business. The Company records provisions that reflect management’s best estimate of any potential liability relating to these matters. The resolution of these matters is not expected to have a material adverse effect on the Company’s financial position, results of operations or cash flows.

Pensions

Pensions	9 Months Ended
	Sep. 30, 2024
Pensions
Pensions	17. Pensions: The Company has adopted a defined contribution pension plan for its employees whereby the Company matches contributions made by participating employees up to a maximum of 3.5% of such employees’ annual salaries. During the three and nine months ended September 30, 2024, contributions which were recorded as expenses within direct center and patient care costs, other regional and center support costs and corporate, general and administrative expenses, amounted to $244,287 and $690,248, respectively- (three and nine months ended September 30, 2023 – $177,391 and $553,300, respectively).

Income taxes

Income taxes	9 Months Ended
	Sep. 30, 2024
Income taxes
Income taxes	18. Income taxes: During the nine months ended September 30, 2024, there were no significant changes to the Company’s tax position.

Risk management arising from fi

Risk management arising from financial instruments	9 Months Ended
	Sep. 30, 2024
Risk management arising from financial instruments
Risk management arising from financial instruments	19. Risk management arising from financial instruments: In the normal course of business, the Company is exposed to risks related to financial instruments that can affect its operating performance. These risks, and the actions taken to manage them, are as follows: (a) Fair value: The Company has Level 1 financial instruments which consists of cash, restricted cash, accounts receivable, accounts payable and accrued liabilities, PA Settlement Agreement and Neuronetics Transaction Costs which approximate their fair value given their short-term nature. The Company also has lender warrants and DSUs that are considered Level 2 financial instruments (see note 11). The Company has deferred and contingent consideration (note 12) that are considered Level 3 financial instruments. The carrying value of the loans payable, shareholder loans and finance lease obligations approximates their fair value given the difference between the discount rates used to recognize the liabilities in the condensed interim consolidated balance sheets and the market rates of interest is insignificant. Financial instruments are classified into one of the following categories: financial assets or financial liabilities. (b) Credit risk: Credit risk arises from the potential that a counterparty will fail to perform its obligations. The Company is exposed to credit risk from patients and third-party payors including federal and state agencies (under the Medicare programs), managed care health plans and commercial insurance companies. The Company’s exposure to credit risk is mitigated in large part due to the majority of the accounts receivable balance being receivable from large, creditworthy medical insurance companies and government-backed health plans. The Company’s aging schedule in respect of its accounts receivable balance as at September 30, 2024 and December 31, 2023 is provided below: Days since service delivered September 30, December 31, 0 – 90 $ 10,592,724 $ 5,954,636 91 – 180 1,279,098 1,013,083 181 – 270 487,503 379,772 270+ 268,953 222,352 Total accounts receivable $ 12,628,278 $ 7,569,843 Based on the Company’s industry, none of the accounts receivable in the table above are considered “past due”. Furthermore, the payors have the ability and intent to pay, but price lists for the Company’s services are subject to the discretion of payors. As such, the timing of collections is not linked to increased credit risk. The Company continues to collect on services rendered in excess of 24 months from the date such services were rendered. (c) Liquidity risk: Liquidity risk is the risk that the Company may encounter difficulty in raising funds to meet its financial commitments or can only do so at excessive cost. The Company ensures there is sufficient liquidity to meet its short-term business requirements, taking into account its anticipated cash flows from operations, its holdings of cash and its ability to raise capital from existing or new investors and/or lenders (see note 2(a)). (d) Currency risk: Currency risk is the risk to the Company’s earnings that arises from fluctuations in foreign exchange rates and the degree of volatility of those rates. The Company has minimal exposure to currency risk as substantially all of the Company’s revenue, expenses, assets and liabilities are denominated in U.S. dollars. The Company pays certain vendors and payroll costs in Canadian dollars from time to time, but due to the limited size and nature of these payments it does not give rise to significant currency risk. (e) Interest rate risk: Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to changes in interest rates on its cash and long-term debt. Certain loans payable (see note 9) bear interest at a rate equal to the 3-month would

Capital management

Capital management	9 Months Ended
	Sep. 30, 2024
Capital management
Capital management	20. Capital management: The Company’s objective is to maintain a capital structure that supports its long-term growth strategy, maintains creditor and customer confidence, and maximizes shareholder value. The capital structure of the Company consists of its shareholders’ equity, including contributed surplus and deficit, as well as loans payable and shareholder loans. The Company’s primary uses of capital are to finance operations, finance new center start-up non-cash

Related party transactions

Related party transactions	9 Months Ended
	Sep. 30, 2024
Related party transactions
Related party transactions	21. Related party transactions: (a) Transactions with significant shareholder – Greybrook Health As at September 30, 2024, nil is included in accounts payable and accrued liabilities for amounts payable for management services rendered and other overhead costs incurred by Greybrook Health in the ordinary course of business (December 31, 2023 – $4,884). These amounts were recorded at their exchange amount, being the amount agreed to by the parties. During the three and nine months ended September 30, 2024, the Company recognized nil and nil, respectively, in corporate, general and administrative expenses (three and nine months ended September 30, 2023 – $1,788 and $5,011, respectively) related to transactions with Greybrook Health. (b) Loans from shareholder – Greybrook Health In connection with the February 2023 Notes, the February 2023 Greybrook Note and the August 2023 Greybrook Note, the Company received loans from and issued promissory notes to Greybrook Health, who is a significant shareholder of the Company. The February 2023 Notes, the February 2023 Greybrook Note and the August 2023 Greybrook Note total $2,437,604 and were exchanged on August 28, 2023 for Subordinated Convertible Notes with the same principal amount. As additional consideration for the February 2023 Greybrook Note, the Company issued 135,870 February 2023 Greybrook Warrants to Greybrook Health and as consideration for the August 2023 Greybrook Note, the Company issued 250,000 August 2023 Greybrook Warrants to Greybrook Health. On August 15, 2023, the Company issued Subordinated Convertible Notes to Greybrook Health in an aggregate amount of $500,000. In addition, on August 28, 2023, the total par value of $2,437,604 of the previously issued February 2023 Notes, the February 2023 Greybrook Note, and the August 2023 Greybrook Note were exchanged for Subordinated Convertible Notes. See note 10(a), note 10(b) and note 15(b). During the three and nine months ended September 30, 2024, the Company recognized $119,501 and $348,470, respectively, in interest expense (three and nine months ended September 30, 2023 – $92,333 and $166,362, respectively) related to the February 2023 Notes, the February 2023 Greybrook Note, the August 2023 Greybrook Note and the Subordinated Convertible Notes issued to Greybrook Health. On October 3, 2024, all outstanding Subordinated Convertible Notes, including Subordinated Convertible Notes held by Greybrook Health, were converted into Common Shares following the receipt of a conversion notice from Madryn. In connection therewith, a total of 43,739,148 Common Shares were issued to Greybrook Health at a conversion price of $0.078 per Common Share. See note 25. (c) Transactions with the former significant shareholder, former officer and former director – Benjamin Klein As at September 30, 2024, nil is included in accounts payable and accrued liabilities for amounts payable for travel expenses and other related costs incurred by Benjamin Klein in the ordinary course of business (December 31, 2023 – nil). During the three and nine months ended September 30, 2024, the Company recognized nil and nil, respectively, in corporate, general and administrative expenses (three and nine months ended September 30, 2023 – $76,921 and $229,178, respectively) for amounts payable for employment services rendered and other related costs incurred by Benjamin Klein in the ordinary course of business. On August 9, 2024, the Company entered into the PA Settlement Agreement. See note 11 and note 14. (d) Loan from former significant shareholder, former officer and former director – Benjamin Klein On July 14, 2022, in connection with the Success TMS Acquisition, the Company assumed the obligation to repay the Klein Note to Benjamin Klein, who is a significant shareholder of the Company. On November 20, 2023, the Company entered into a settlement agreement in respect of the Klein Note. See note 11(e). The Klein Note totaled $2,090,264 and had an interest rate of 10% per annum and matured on May 1, 2024. The carrying amount of the Klein Note as at September 30, 2024 is nil (December 31, 2023 – nil). During the three and nine months ended September 30, 2024, the Company recognized nil and nil, respectively, in interest expense (three and nine months ended September 30, 2023 – $64,175 and $191,485, respectively) related to the Klein Note. (e) Loans from shareholders and officers The February 2023 Notes (not including Greybrook Health’s contribution) totaling $312,396 were exchanged for Subordinated Convertible Notes on August 28, 2023. The carrying amount of the Subordinated Convertible Notes issued to shareholders and officers (excluding Greybrook Health and Madryn) as at September 30, 2024 is $335,318 (December 31, 2023 – $328,026). See note 9(a) and note 10(b). During the three and nine months ended September 30, 2024, the Company recognized $11,499 and $33,542 respectively, in interest expense (three and nine months ended September 30, 2023 – $14,323 and $32,654, respectively) related to these Subordinated Convertible Notes. On October 3, 2024, all outstanding Subordinated Convertible Notes, including Subordinated Convertible Notes held by certain officers of the Company, were converted into Common Shares following the receipt of a conversion notice from Madryn. In connection therewith, a total of 1,115,728 Common Shares were issued to officers of the Company at a conversion price of $0.078 per Common Share. See note 25. (f) Loan from significant shareholder – Madryn On July 14, 2022, the Company entered into the Madryn Credit Agreement in respect of the Madryn Credit Facility, which was subsequently amended, for a total principal balance of $118,949,913 as at September 30, 2024, including the amendment fee of $1,000,000 (December 31, 2023 – $82,731,638). This amount does not include the other financing and legal fees associated with each term loan issuance or the interest that has accrued on the principal balance of the Credit Facility which has been paid in kind. Pursuant to the 2023 Private Placement completed on March 23, 2023, Madryn became a significant shareholder of the Company. See note 9(a). On August 15, September 1 and October 12, 2023, the Company issued Subordinated Convertible Notes to Madryn in an aggregate amount of $4,500,000. The Subordinated Convertible Notes bear interest at a rate consistent with the Madryn Credit Facility, are convertible according to the terms of the Note Purchase Agreement and mature on the earlier of March 31, 2028, in the event of a change of control, acceleration of other indebtedness, or six months following repayment or refinancing of all loans under the Madryn Credit Facility. See note 9(a). During the three and nine months ended September 30, 2024, the Company recognized $187,366 and $546,061, respectively, in interest expense (three and nine months ended September 30, 2023 – $47,044 and $47,044, respectively) related to the Subordinated Convertible Notes issued to Madryn. Pursuant to the Arrangement Agreement entered into on August 12, 2024, Madryn has agreed to convert all of the amount outstanding under the Madryn Credit Facility and the Subordinated Convertible Notes into Common Shares, prior to the effective date of the Neuronetics Transaction. See note 14. On October 3, 2024, all outstanding Subordinated Convertible Notes, including Subordinated Convertible Notes

Basic and diluted loss per shar

Basic and diluted loss per share	9 Months Ended
	Sep. 30, 2024
Basic and diluted loss per share
Basic and diluted loss per share	22. Basic and diluted loss per share: Three months ended Nine months ended September 30, September 30, September 30, September 30, 2024 2023 2024 2023 Net loss attributable to the shareholders of Greenbrook TMS $ (13,207,359 ) $ (13,491,287 ) $ (39,830,850 ) $ (36,824,871 ) Weighted average common shares outstanding: Basic and diluted 39,721,003 42,232,942 43,061,687 37,810,209 Loss per share: Basic and diluted $ (0.33 ) $ (0.32 ) $ (0.92 ) $ (0.97 ) For the three and nine months ended September

Non-controlling interest

Non-controlling interest	9 Months Ended
	Sep. 30, 2024
Non-controlling interest
Non-controlling interest	23. Non-controlling As a result of operating agreements with non-wholly The following summarizes changes in the Company’s non-wholly (a) On February 27, 2023, the Company acquired a portion of the non-controlling (b) On September 29, 2023, the Company acquired a portion of the non-controlling non-controlling (c) On April 18, 2024, the Company acquired a portion of the non-controlling (d) On April 18, 2024, the Company acquired a portion of the non-controlling (e) On May 17, 2024, the Company acquired a portion of the non-controlling (f) On May 17, 2024, the Company acquired a portion of the non-controlling (g) On May 17, 2024, the Company acquired a portion of the non-controlling (h) On May 17, 2024, the Company acquired a portion of the non-controlling (i) On June 3, 2024, the Company acquired a portion of the non-controlling (j) On June 3, 2024, the Company acquired a portion of the non-controlling (k) On June 3, 2024, the Company acquired a portion of the non-controlling The following table summarizes the aggregate financial information for the Company’s non-wholly September 30, December 31, Cash $ 172,341 $ 97,702 Accounts receivable, net 4,977,643 2,144,953 Prepaid expenses and other 408,155 297,485 Property, plant and equipment 924,260 1,000,592 Finance right-of-use —  36,165 Operating right-of-use 5,310,005 5,656,153 Accounts payable and accrued liabilities 1,597,561 1,239,917 Finance lease liabilities —  10,548 Operating lease liabilities 5,622,097 5,968,042 Loans payable, net 16,534,707 15,828,916 Shareholder’s deficit attributable to the shareholders of Greenbrook TMS (8,358,893 ) (10,902,792 ) Shareholder’s deficit attributable to non-controlling (4,258,434 ) (4,440,274 ) Distributions paid to non-controlling (201,000 ) (46,950 ) Partnership buyout (466,026 ) 253,251 Historical subsidiary investment by non-controlling 1,322,392 1,322,392 The following table summarizes the aggregate financial information for the Company’s non-wholly Three months ended Nine months ended September 30, September 30, September 30, September 30, Revenue $ 8,337,782 $ 5,561,769 $ 20,184,728 $ 18,473,712 Net gain (loss) attributable to the shareholders of Greenbrook TMS 474,492 (311,254 ) (776,242 ) (1,353,456 ) Net gain (loss) attributable to non-controlling 328,018 (66,025 ) (24,461 ) (249,575 )

Expenses by nature

Expenses by nature	9 Months Ended
	Sep. 30, 2024
Operating Expenses [Abstract]
Expenses by nature	24. Expenses by nature: The components of the Company’s other regional and center support costs include the following: Three months ended Nine months ended September 30, September 30, September 30, September 30, Salaries and bonuses $ 5,506,017 $ 4,356,592 $ 16,703,081 $ 13,129,558 Marketing expenses 1,717,372 407,538 3,941,952 1,224,139 Total $ 7,223,389 $ 4,764,130 $ 20,645,033 $ 14,353,697 The components of the Company’s corporate, general and administrative expenses include the following: Three months ended Nine months ended September 30, September 30, September 30, September 30, Salaries and bonuses $ 3,760,881 $ 3,629,623 $ 11,671,760 $ 11,880,351 Marketing expenses 49,676 52,237 171,400 83,504 Professional and legal fees 1,119,518 937,735 2,730,955 3,565,048 Computer supplies and software 938,265 659,320 3,503,319 2,091,340 Financing and transaction costs 13,185 100,000 174,662 335,094 Travel, meals and entertainment 62,539 39,994 185,187 121,181 Restructuring expense —  36,500 684,578 500,368 Insurance 51,088 113,909 377,078 476,687 Credit facility amendment fee (note 9(a)) —  —  —  1,000,000 PA Settlement Agreement (note 11(f)) —  —  800,000 —  Other 296,506 416,743 1,171,134 1,351,549 Total $ 6,291,658 $ 5,986,061 $ 21,470,073 $ 21,405,122 On March 6, 2023, the Company announced that it embarked on a comprehensive restructuring plan (the “Restructuring Plan”) that aimed to strengthen the Company by leveraging its scale to further reduce complexity, streamlining its operating model and driving operational efficiencies to achieve profitability. As part of this Restructuring Plan, the Company decreased its operating footprint and headcount and operating expenses. The remaining Treatment Centers will continue clinical TMS offerings and a select and growing number of Treatment Centers will continue offering Spravato ®

Subsequent event

Subsequent event	9 Months Ended
	Sep. 30, 2024
Subsequent event
Subsequent event	25. Subsequent events: (a) Additional loans under Madryn Credit Facility: On October 3, October 15 and November 6, 2024, the Company entered into amendments to the Madryn Credit Facility, whereby Madryn and its affiliated entities extended two additional tranches of debt financing to the Company in an aggregate principal amount of $5,106,599. The terms and conditions are consistent with the terms and conditions of the Company’s existing aggregate term loan, with a principal balance of $120,990,522, under the Madryn Credit Facility in all material respects. In addition, the amendment to the Madryn Credit Facility entered into on November 27, 2024, extended the period during which the Company’s minimum liquidity covenant is reduced from $3,000,000 to $300,000 to December 9, 2024. (b) Subordinated Convertible Notes Conversion: On October 3, 2024, the Company converted all outstanding Subordinated Convertible Notes into Common Shares upon receipt of a conversion notice from Madryn, requiring the conversion in full of all outstanding Subordinated Convertible Notes held by Madryn and all other holders of Subordinated Convertible Notes in accordance with the terms of the Note Purchase Agreement. The Subordinated Convertible Notes were converted into Common Shares at a conversion price of $0.078 and resulted in the issuance of an aggregate of 134,667,522 Common Shares to the holders of the Convertible Notes. Following completion of the conversion, there are no Subordinated Convertible Notes, or accrued and unpaid interest, issued and outstanding. (c) Neuronetics Transaction: On October 1, 2024, the Court granted an interim order in connection with the Neuronetics Transaction (the “Interim Order”). The Interim Order authorizes the calling and holding of the Greenbrook Meeting, the granting of dissent rights to registered shareholders of the Company and other matters relating to the conduct of the Greenbrook Meeting. The Greenbrook Meeting was called for Friday, November 8, 2024 at 8:00 a.m. (Eastern time). On October 4, 2024, the Company and Neuronetics filed the joint proxy statement/management information circular (the “Joint Proxy Statement/Circular”) and related proxy materials in respect of the Greenbrook Meeting and Neuronetics Meeting on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. The Joint Proxy Statement/Circular and related materials were also be mailed to shareholders. On November 8, 2024, the Neuronetics Transaction was approved by the shareholders of the Company and the stockholders of Neuronetics at the Greenbrook Meeting and the Neuronetics Meeting, respectively. On November 15, 2024, the Company obtained a final order from the Ontario Superior Court of Justice (Commercial List) approving the Neuronetics Transaction. On December 10, 2024, the Company announced the successful completion of the Neuronetics Transaction with an effective date of December 9, 2024. In connection with and prior to closing of the Arrangement, Madryn converted (i) all of the outstanding amount owing under Greenbrook’s credit agreement into 2,056,453,835 Greenbrook Shares, representing 95.3% of the Greenbrook Shares (including the Greenbrook Shares held by Madryn prior to such conversion) immediately prior to closing of the Arrangement and (ii) all of the interim period funding provided by Madryn to Greenbrook into an additional 252,999,770 Greenbrook Shares, which Greenbrook Shares were exchanged for Neuronetics Shares at the Exchange Ratio upon closing of the Arrangement. (d) Supplement Restructuring Plan: On November 15, 2024, the Company began a supplemental restructuring plan (the “Supplemental Restructuring Plan”) in an effort to continue to accelerate its path to achieve sustainable profitability and long-term growth. As part of this initiative, the Company plans to decrease its operating footprint by closing 23 treatment centers over the next 45 days, allowing management to focus on its remaining 95 treatment centers.

Description of the Transaction

Description of the Transaction	9 Months Ended
	Sep. 30, 2024
Description of the transaction	1. Reporting entity: Greenbrook TMS Inc. (the “Company”), an Ontario corporation along with its subsidiaries, controls and operates a network of outpatient mental health services centers that specialize in the provision of Transcranial Magnetic Stimulation (“TMS”) therapy and other treatment modalities for the treatment of depression and related psychiatric services. The Company’s head and registered office is located at 890 Yonge Street, 7th Floor, Toronto, Ontario, Canada, M4W 3P4. The Company’s United States corporate headquarters is located at 8401 Greensboro Drive, Suite 425, Tysons Corner, Virginia, USA, 22102.
Pro Forma [Member]
Description of the transaction	1. Description of the Transaction Neuronetics and Greenbrook TMS Inc. completed the planned acquisition whereby Neuronetics acquired all of the issued and outstanding common shares of Greenbrook by way of a court-approved plan of arrangement under the Business Corporations Act (Ontario) (the “Arrangement”). Each Greenbrook Share outstanding immediately prior to the effective time of the Arrangement was exchanged for 0.01021 of a share of common stock of Neuronetics (the “Exchange Ratio”) upon closing of the Arrangement. In connection with and prior to closing of the Arrangement, Madryn Asset Management, LP and its affiliates (collectively, “Madryn”) converted (i) all of the outstanding amount owing under Greenbrook’s credit agreement into 2,056,453,835 Greenbrook Shares, representing 95.3% of the Greenbrook Shares (including the Greenbrook Shares held by Madryn prior to such conversion) immediately prior to closing of the Arrangement and (ii) all of the interim period funding provided by Madryn to Greenbrook into an additional 252,999,770 Greenbrook Shares, which Greenbrook Shares were exchanged for shares of common stock of Neuronetics (“Neuronetics Shares”) at the Exchange Ratio upon closing of the Arrangement. The Combined Company will continue to operate as Neuronetics, Inc., and the Neuronetics Shares will continue to trade on the NASDAQ Global Market under the ticker “STIM”.

Preliminary Purchase Price Allo

Preliminary Purchase Price Allocation	9 Months Ended
	Sep. 30, 2024
Pro Forma [Member]
Preliminary Purchase Price Allocation	3. Preliminary Purchase Price Allocation The fair value of the total consideration was approximately $34.7 million consisting of the following: Purchase Consideration STIM Shares 25,305 Price per share $ 1.15 Fair value of purchase consideration paid at closing $ 29,101 Settlement of pre- $ 5,635 Total purchase consideration $ 34,736 The preliminary purchase price allocation is based on estimates, assumptions, valuations and other analysis which have not yet been finalized. The Company is finalizing its valuation of intangible assets, tangible assets, liabilities and tax analyses and anticipates finalizing the valuation of assets acquitted and liabilities assumed as the information necessary to complete the analysis is obtained, but no later than one year after the Acquisition Date. The following table set forth the preliminary allocation of the total con si Fair Value Fair value of assets acquired Cash and cash equivalents $ 369 Restricted cash $ 1,000 Accounts receivable, net $ 12,628 Prepaid expenses and other current assets $ 4,990 Property and equipment $ 4,725 Operating lease right-of-use $ 23,658 Total Assets $ 47,370 Fair value of liabilities assumed Accounts payable $ 8,673 Accrued expense $ 4,385 Current portion of loans payable $ 801 Current portion of operating lease liabilities $ 4,044 Deferred and contingent consideration $ 1,000 Operating lease liabilities $ 21,139 Non-controlling $ (3,603 ) Total Liabilities $ 36,438 Total identifiable net assets acquired $ 10,932 Goodwill $ 23,803 Total consideration transferred $ 34,736

Proforma Adjustments

Proforma Adjustments	9 Months Ended
	Sep. 30, 2024
Pro Forma [Member]
Proforma Adjustments	4. Proforma Adjustments The pro forma adjustments are based on the Company’s preliminary estimates and assumptions that are subject to change. The following adjustments have been reflected in the Pro Forma Financial Statements: 1. Certain reclassifications of Greenbrook’s historically presented amounts were made within the balance sheet and statements of operations to conform with Neuronetics’ financial statement presentation. 2. The pro forma adjustments included in the unaudited pro forma combined financial information are as follows (amounts in thousands): a) Reflects the elimination of Greenbrook’s historical equity balances in accordance with the acquisition method of accounting. b) Reflects estimated consideration based upon issuance of 25,304,971 shares at a price of $1.15 as of December 09, 2024 c) To reflect the estimated fair value of the assets acquired and liabilities d)  To recognize Greenbrook’s lease liability and right-of- e) To reflect the conversion of certain debt instruments to Goodwill, as non cash consideration f) To reflect conversion of Neuronetics Note receivable to Greenbook as of September 30, 2024 to Goodwill, as non cash consideration g) To reflect conversion of Neuronetics Sales type leases with Greenbook to PPE as of September 30, 2024. h) To eliminate Neuronetics interest receivable with Greenbrook and Greenbrook’s prepaid warranty and treatment session inventory balances. i) To eliminate Greenbrook’s finance lease right-of- aa) To eliminate sales to Greenbrook. bb) To eliminate cost of sales to Greenbrook. cc) To eliminate depreciation expense for Greenbrook’s finance leases. dd) To eliminate interest expense for Greenbrook’s debt balance. ee) To eliminate interest charged to Greenbrook by Neuronetics for Note receivable balance ff) To reclassify marketing expense reported in Cost of revenue to Sales and marketing expense.

Significant accounting polici_2

Significant accounting policies (Policies)	9 Months Ended
	Sep. 30, 2024
Material accounting policies
Revenue recognition	(a) Revenue recognition: Other revenue is recognized at a point in time upon the performance of services under contracts with customers and represents the consideration to which the Company expects to be entitled. Other revenue includes revenue from research agreements. Research agreements consist of arrangements with other companies to perform studies and investigational tasks on the delivery and scalability of various treatment modalities. Revenue related to research agreements is recognized based on the completion of pre-set

Property, plant and equipment (

Property, plant and equipment (Tables)	9 Months Ended
	Sep. 30, 2024
Property, plant and equipment
Property, plant and equipment	Leasehold TMS devices Total Cost Balance, December 31, 2023 $ 359,662 $ 6,427,908 $ 6,787,570 Additions —  699,903 699,903 Asset Disposal (8,950 ) (80,000 ) (88,950 ) Balance, September 30, 2024 $ 350,712 $ 7,047,811 $ 7,398,523 Accumulated depreciation Balance, December 31, 2023 $ 156,540 $ 1,837,051 $ 1,993,591 Depreciation 46,078 722,369 768,447 Asset Disposal (8,950 ) (80,000 ) (88,950 ) Balance, September 30, 2024 $ 193,668 $ 2,479,420 $ 2,673,088 Net book value Balance, December 31, 2023 $ 203,122 $ 4,590,857 $ 4,793,979 Balance, September 30, 2024 157,044 4,568,391 4,725,435

Intangible assets (Tables)

Intangible assets (Tables)	9 Months Ended
	Sep. 30, 2024
Intangible assets
Schedule of Intangible assets	Management Covenant not Total Cost Balance, December 31, 2023 $ 2,792,178 $ 355,238 $ 3,147,416 Additions —  —  —  Asset Disposal —  (355,238 ) (355,238 ) Balance, September 30, 2024 $ 2,792,178 $ —  $ 2,792,178 Accumulated amortization Balance, December 31, 2023 $ 2,176,641 $ 348,718 $ 2,525,359 Amortization 43,000 6,520 49,520 Asset Disposal —  (355,238 ) (355,238 ) Balance, September 30, 2024 $ 2,219,641 $ —  $ 2,219,641 Net book value Balance, December 31, 2023 $ 615,537 $ 6,520 $ 622,057 Balance, September 30, 2024 572,537 —  572,537

Right-of-use assets and lease_2

Right-of-use assets and lease liabilities (Tables)	9 Months Ended
	Sep. 30, 2024
Right-of-use assets and lease liabilities
Schedule of finance right-of-use assets	September 30, Finance right-of-use $ 2,140,338 Impact of lease additions, disposals and/or modifications —  Exercise of buy-out (699,903 ) Depreciation on right-of-use (163,614 ) Finance right-of-use $ 1,276,821 September 30, Finance lease liabilities, beginning of the period $ 857,837 Impact of lease additions, disposals and/or modifications 10,601 Interest expense on lease liabilities 48,749 Payments of lease liabilities (541,492 ) Finance lease liabilities, end of the period $ 375,695 Less current portion of finance lease liabilities 355,161 Long term portion of finance lease liabilities $ 20,534
Schedule of finance lease liabilities	September 30, Finance right-of-use $ 2,140,338 Impact of lease additions, disposals and/or modifications —  Exercise of buy-out (699,903 ) Depreciation on right-of-use (163,614 ) Finance right-of-use $ 1,276,821 September 30, Finance lease liabilities, beginning of the period $ 857,837 Impact of lease additions, disposals and/or modifications 10,601 Interest expense on lease liabilities 48,749 Payments of lease liabilities (541,492 ) Finance lease liabilities, end of the period $ 375,695 Less current portion of finance lease liabilities 355,161 Long term portion of finance lease liabilities $ 20,534
Schedule of operating right-of-use assets	September 30, Operating right-of-use $ 28,887,905 Impact of lease additions, disposals and/or modifications (2,125,346 ) Right-of-use (3,104,371 ) Operating right-of-use $ 23,658,188 September 30, Operating lease liabilities, beginning of the period $ 30,398,566 Impact of lease additions, disposals and/or modifications (2,180,550 ) Lease liability expense 2,389,817 Payments of lease liabilities (5,425,421 ) Operating lease liabilities, end of the period 25,182,412 Less current portion of operating lease liabilities 4,043,583 Long term portion of operating lease liabilities $ 21,138,829
Schedule of operating lease liabilities	September 30, Operating right-of-use $ 28,887,905 Impact of lease additions, disposals and/or modifications (2,125,346 ) Right-of-use (3,104,371 ) Operating right-of-use $ 23,658,188 September 30, Operating lease liabilities, beginning of the period $ 30,398,566 Impact of lease additions, disposals and/or modifications (2,180,550 ) Lease liability expense 2,389,817 Payments of lease liabilities (5,425,421 ) Operating lease liabilities, end of the period 25,182,412 Less current portion of operating lease liabilities 4,043,583 Long term portion of operating lease liabilities $ 21,138,829

Accounts payable and accrued _2

Accounts payable and accrued liabilities (Tables)	9 Months Ended
	Sep. 30, 2024
Accounts payable and accrued liabilities
Schedule of accounts payable and accrued liabilities	September 30, December 31, Accounts payable $ 10,563,496 $ 9,050,616 Accrued liabilities 4,385,207 4,651,014 Total $ 14,948,703 $ 13,701,630

Loans payable (Tables)

Loans payable (Tables)	9 Months Ended
	Sep. 30, 2024
Loans payable.
Schedule of bank loans	TMS Credit Promissory Neuronetics Total Short Term $ 6,696 —  $ 7,412,790 $ 4,000,000 $ 11,419,486 Long Term —  131,595,084 178,981 —  131,774,065 Total, net $ 6,696 $ 131,595,084 $ 7,591,771 $ 4,000,000 $ 143,193,551 Unamortized capitalized financing costs —  2,907,505 151,081 —  3,058,586 Total, September 30, 2024 $ 6,696 $ 134,502,589 $ 7,742,852 $ 4,000,000 $ 146,252,137
Schedule of non-controlling interest loans	September 30, December 31, Non-controlling $ 58,074 $ 63,174

Other payables (Tables)

Other payables (Tables)	9 Months Ended
	Sep. 30, 2024
Other Liabilities Disclosure [Abstract]
Schedule of Lender Warrants	September 30, December 31, Lender warrants $ —  $ —
Schedule of Deferred share units	September 30, December 31, Deferred share units $ 43,460 $ 376,565
Schedule of Performance share units	September 30, December 31, Performance share units $ —  $ 1,047
Schedule of Device contract termination	September 30, December 31, Device contract termination $ —  $ 3,750,000
Schedule of Klein Note settlement payable	September 30, December 31, Klein Note settlement $ —  $ 1,603,169
Schedule of PA Settlement Agreement	September 30, December 31, PA Settlement Agreement $ 533,333 $ —
Schedule of Neuronetics Transaction Costs	September 30, December 31, Neuronetics Transaction Costs $ 1,370,602 $ —

Deferred and contingent consi_2

Deferred and contingent consideration (Tables)	9 Months Ended
	Sep. 30, 2024
Deferred and contingent consideration
Schedule of deferred and contingent consideration	September 30, December 31, Deferred and contingent consideration $ 1,000,000 $ 1,000,000

Advance for research collabor_2

Advance for research collaboration (Tables)	9 Months Ended
	Sep. 30, 2024
Advance for research collaboration.
Schedule of advance for research collaboration	September 30, December 31, Advance for research collaboration $ —  $ 1,300,000

Common shares (Tables)

Common shares (Tables)	9 Months Ended
	Sep. 30, 2024
Common shares
Schedule of common shares	Number Total December 31, 2023 42,774,011 $ 120,741,061 Issuance of Common Shares – February 2024 Direct Offering 2,828,249 495,649 Surrender and Cancellation of Common Shares – PA Settlement Agreement (11,634,660 ) —  September 30, 2024 33,967,600 $ 121,236,710

Contributed surplus (Tables)

Contributed surplus (Tables)	9 Months Ended
	Sep. 30, 2024
Contributed surplus
Schedule of stock options outstanding activity	September 30, 2024 December 31, 2023 Number of Weighted Number of Weighted Outstanding, beginning of period 1,704,500 $ 3.11 764,667 $ 8.15 Granted 575,000 0.10 1,313,000 0.63 Forfeited (55,000 ) (0.75 ) (373,167 ) (4.71 ) Expired (5,000 ) (0.75 ) —  —  Outstanding, end of period 2,219,500 $ 2.39 1,704,500 $ 3.11

Risk management arising from _2

Risk management arising from financial instruments (Tables)	9 Months Ended
	Sep. 30, 2024
Risk management arising from financial instruments
Schedule of aging in respect of accounts receivable balance	Days since service delivered September 30, December 31, 0 – 90 $ 10,592,724 $ 5,954,636 91 – 180 1,279,098 1,013,083 181 – 270 487,503 379,772 270+ 268,953 222,352 Total accounts receivable $ 12,628,278 $ 7,569,843

Basic and diluted loss per sh_2

Basic and diluted loss per share (Tables)	9 Months Ended
	Sep. 30, 2024
Basic and diluted loss per share
Schedule of basic and diluted loss per share	Three months ended Nine months ended September 30, September 30, September 30, September 30, 2024 2023 2024 2023 Net loss attributable to the shareholders of Greenbrook TMS $ (13,207,359 ) $ (13,491,287 ) $ (39,830,850 ) $ (36,824,871 ) Weighted average common shares outstanding: Basic and diluted 39,721,003 42,232,942 43,061,687 37,810,209 Loss per share: Basic and diluted $ (0.33 ) $ (0.32 ) $ (0.92 ) $ (0.97 )

Non-controlling interest (Table

Non-controlling interest (Tables)	9 Months Ended
	Sep. 30, 2024
Non-controlling interest
Schedule of balance sheet financial information of non controlling interest	The following table summarizes the aggregate financial information for the Company’s non-wholly September 30, December 31, Cash $ 172,341 $ 97,702 Accounts receivable, net 4,977,643 2,144,953 Prepaid expenses and other 408,155 297,485 Property, plant and equipment 924,260 1,000,592 Finance right-of-use —  36,165 Operating right-of-use 5,310,005 5,656,153 Accounts payable and accrued liabilities 1,597,561 1,239,917 Finance lease liabilities —  10,548 Operating lease liabilities 5,622,097 5,968,042 Loans payable, net 16,534,707 15,828,916 Shareholder’s deficit attributable to the shareholders of Greenbrook TMS (8,358,893 ) (10,902,792 ) Shareholder’s deficit attributable to non-controlling (4,258,434 ) (4,440,274 ) Distributions paid to non-controlling (201,000 ) (46,950 ) Partnership buyout (466,026 ) 253,251 Historical subsidiary investment by non-controlling 1,322,392 1,322,392
Schedule of comprehensive loss financial information of non controlling interest	The following table summarizes the aggregate financial information for the Company’s non-wholly Three months ended Nine months ended September 30, September 30, September 30, September 30, Revenue $ 8,337,782 $ 5,561,769 $ 20,184,728 $ 18,473,712 Net gain (loss) attributable to the shareholders of Greenbrook TMS 474,492 (311,254 ) (776,242 ) (1,353,456 ) Net gain (loss) attributable to non-controlling 328,018 (66,025 ) (24,461 ) (249,575 )

Expenses by nature (Tables)

Expenses by nature (Tables)	9 Months Ended
	Sep. 30, 2024
Operating Expenses [Abstract]
Schedule of components of the Company's other regional and center support costs	Three months ended Nine months ended September 30, September 30, September 30, September 30, Salaries and bonuses $ 5,506,017 $ 4,356,592 $ 16,703,081 $ 13,129,558 Marketing expenses 1,717,372 407,538 3,941,952 1,224,139 Total $ 7,223,389 $ 4,764,130 $ 20,645,033 $ 14,353,697
Schedule of components of the Company's corporate, general and administrative expenses	Three months ended Nine months ended September 30, September 30, September 30, September 30, Salaries and bonuses $ 3,760,881 $ 3,629,623 $ 11,671,760 $ 11,880,351 Marketing expenses 49,676 52,237 171,400 83,504 Professional and legal fees 1,119,518 937,735 2,730,955 3,565,048 Computer supplies and software 938,265 659,320 3,503,319 2,091,340 Financing and transaction costs 13,185 100,000 174,662 335,094 Travel, meals and entertainment 62,539 39,994 185,187 121,181 Restructuring expense —  36,500 684,578 500,368 Insurance 51,088 113,909 377,078 476,687 Credit facility amendment fee (note 9(a)) —  —  —  1,000,000 PA Settlement Agreement (note 11(f)) —  —  800,000 —  Other 296,506 416,743 1,171,134 1,351,549 Total $ 6,291,658 $ 5,986,061 $ 21,470,073 $ 21,405,122

Preliminary Purchase Price Al_2

Preliminary Purchase Price Allocation (Tables) - Pro Forma [Member]	9 Months Ended
	Sep. 30, 2024
Schedule of Fair value of the total consideration	The fair value of the total consideration was approximately $34.7 million consisting of the following: Purchase Consideration STIM Shares 25,305 Price per share $ 1.15 Fair value of purchase consideration paid at closing $ 29,101 Settlement of pre- $ 5,635 Total purchase consideration $ 34,736
Schedule of Preliminary allocation of the total consideration	The following table set forth the preliminary allocation of the total con si Fair Value Fair value of assets acquired Cash and cash equivalents $ 369 Restricted cash $ 1,000 Accounts receivable, net $ 12,628 Prepaid expenses and other current assets $ 4,990 Property and equipment $ 4,725 Operating lease right-of-use $ 23,658 Total Assets $ 47,370 Fair value of liabilities assumed Accounts payable $ 8,673 Accrued expense $ 4,385 Current portion of loans payable $ 801 Current portion of operating lease liabilities $ 4,044 Deferred and contingent consideration $ 1,000 Operating lease liabilities $ 21,139 Non-controlling $ (3,603 ) Total Liabilities $ 36,438 Total identifiable net assets acquired $ 10,932 Goodwill $ 23,803 Total consideration transferred $ 34,736

Basis of presentation - Going c

Basis of presentation - Going concern (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Basis of presentation
Cashflow from operating activities	$ 36,809,738	$ 20,224,880
Cash Balance	368,512		$ 3,323,708
Working capital	$ 17,818,245		$ 17,681,089

Basis of presentation - Going_2

Basis of presentation - Going concern - Credit Facility (Details) - Madryn term loan	Jul. 14, 2022 USD ($)
Debt Instruments
Secured credit facility, maximum borrowing capacity	$ 75,000,000
Proceeds from term loan	55,000,000
Additional draw amount permitted	$ 20,000,000

Basis of presentation - Going_3

Basis of presentation - Going Concern - Private Placement (Details)	Mar. 23, 2023 USD ($)
2023 Private Placement
Basis of presentation
Proceeds from private placement	$ 6,250,000

Basis of presentation - Going_4

Basis of presentation - Going concern - Alumni Purchase Agreement (Details) - USD ($)		3 Months Ended			9 Months Ended
	Jul. 13, 2023	Mar. 31, 2024	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Basis of presentation
Issuance of common stock shares		$ 495,649	$ 481,437	$ 6,139,262	$ 495,649
Issuance of common shares (note 14) (in shares)					2,828,249
Gross proceeds					$ 495,649	$ 6,620,699
Alumni purchase agreement | Alumni Capital LP
Basis of presentation
Issuance of common stock shares	$ 4,458,156
Issuance of common shares (note 14) (in shares)					1,761,538
Gross proceeds					$ 481,437

Basis of presentation - Going_5

Basis of presentation - Going concern - February 2024 Public Offering (Details) - USD ($)			3 Months Ended			9 Months Ended
	Oct. 03, 2024	Feb. 26, 2024	Mar. 31, 2024	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Nov. 06, 2024	Oct. 15, 2024	Oct. 13, 2023	Feb. 03, 2023
Basis of presentation
Issuance of common shares (note 14) (in shares)						2,828,249
Gross proceeds						$ 495,649	$ 6,620,699
Aggregate debt financing						$ 36,218,275	$ 9,299,000
Aggregate principal amount	$ 5,106,599							$ 5,106,599	$ 5,106,599	$ 6,505,000	$ 750,000
February 2024 Direct Offering
Basis of presentation
Issuance of common shares (note 14) (in shares)		2,828,249
Share price		$ 0.2
Gross proceeds		$ 565,649
Common Stock [Member]
Basis of presentation
Issuance of common shares (note 14) (in shares)			2,828,249	1,973,831	11,363,635
Common Stock [Member] | Convertible Subordinated Debt [Member]
Basis of presentation
Debt Conversion, Converted Instrument, Shares Issued	134,667,522
Debt Instrument, Convertible, Conversion Price	$ 0.078

Property, Plant and equipment_2

Property, Plant and equipment (Details)	9 Months Ended
	Sep. 30, 2024 USD ($)
Cost
Balance at the beginning	$ 6,787,570
Additions	699,903
Asset Disposal	(88,950)
Balance at the end	7,398,523
Accumulated depreciation
Accumulated depreciation at the beginning	1,993,591
Depreciation	768,447
Accumulated depreciation on asset disposal	(88,950)
Accumulated depreciation at the end	2,673,088
Balance at the beginning	4,793,979
Balance at the end	4,725,435
Leasehold improvements
Cost
Balance at the beginning	359,662
Asset Disposal	(8,950)
Balance at the end	350,712
Accumulated depreciation
Accumulated depreciation at the beginning	156,540
Depreciation	46,078
Accumulated depreciation on asset disposal	(8,950)
Accumulated depreciation at the end	193,668
Balance at the beginning	203,122
Balance at the end	157,044
TMS devices
Cost
Balance at the beginning	6,427,908
Additions	699,903
Asset Disposal	(80,000)
Balance at the end	7,047,811
Accumulated depreciation
Accumulated depreciation at the beginning	1,837,051
Depreciation	722,369
Accumulated depreciation on asset disposal	(80,000)
Accumulated depreciation at the end	2,479,420
Balance at the beginning	4,590,857
Balance at the end	$ 4,568,391

Intangible assets (Details)

Intangible assets (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Cost
Beginning balance			$ 3,147,416
Asset Disposal			(355,238)
Ending balance	$ 2,792,178		2,792,178
Accumulated Depreciation
Beginning balance			2,525,359
Amortization	16,426	$ 16,548	49,520	$ 49,643
Asset Disposal			(355,238)
Ending balance	2,219,641		2,219,641
Net book value
Net book value	572,537		572,537		$ 622,057
Management services agreements
Cost
Beginning balance			2,792,178
Ending balance	2,792,178		2,792,178
Accumulated Depreciation
Beginning balance			2,176,641
Amortization			43,000
Ending balance	2,219,641		2,219,641
Net book value
Net book value	572,537		572,537		615,537
Covenants not to compete
Cost
Beginning balance			355,238
Asset Disposal			(355,238)
Ending balance	0		0
Accumulated Depreciation
Beginning balance			348,718
Amortization			6,520
Asset Disposal			(355,238)
Ending balance	0		0
Net book value
Net book value	$ 0		$ 0		$ 6,520

Right-of-use assets and lease_3

Right-of-use assets and lease liabilities - Narratives (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Right-of-use assets and lease liabilities
Lease discount rate (in %)	14.50%	14.50%
Minimum
Right-of-use assets and lease liabilities
Lease term (in years)	1 year
Maximum
Right-of-use assets and lease liabilities
Lease term (in years)	7 years

Right-of-use assets and lease_4

Right-of-use assets and lease liabilities - Finance Right-of-use assets (Details)	9 Months Ended
	Sep. 30, 2024 USD ($)
Right-of-use assets and lease liabilities
Finance right-of-use assets, beginning of the year	$ 2,140,338
Exercise of buy-out options into property, plant and equipment	(699,903)
Depreciation on right-of-use assets	(163,614)
Finance right-of-use assets, end of the year	$ 1,276,821

Right-of-use assets and lease_5

Right-of-use assets and lease liabilities - Finance Lease Liabilities (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Right-of-use assets and lease liabilities
Finance lease liabilities, beginning of the year	$ 857,837
Impact of lease additions, disposals and/or modifications	10,601
Interest expense on lease liabilities	48,749
Payments of lease liabilities	(541,492)
Finance lease liabilities, end of the year	375,695
Less current portion of finance lease liabilities	355,161	$ 622,730
Long term portion of finance lease liabilities	$ 20,534	$ 235,107

Right-of-use assets and lease_6

Right-of-use assets and lease liabilities - Operating Right-of-use assets (Details)	9 Months Ended
	Sep. 30, 2024 USD ($)
Right-of-use assets and lease liabilities
Operating right-of-use assets, beginning of the year	$ 28,887,905
Impact of lease additions, disposals and/or modifications	(2,125,346)
Right-of-use asset lease expense	(3,104,371)
Operating right-of-use assets, ending of the year	$ 23,658,188

Right-of-use assets and lease_7

Right-of-use assets and lease liabilities - Operating Lease Liabilities (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Right-of-use assets and lease liabilities
Operating lease liabilities, beginning of the year	$ 30,398,566
Impact of lease additions, disposals and/or modifications	(2,180,550)
Lease liability expense	2,389,817
Payments of lease liabilities	(5,425,421)
Operating lease liabilities, end of the year	25,182,412
Less current portion of operating lease liabilities	4,043,583	$ 3,960,346
Long term portion of operating lease liabilities	$ 21,138,829	$ 26,438,220

Accounts payable and accrued _3

Accounts payable and accrued liabilities (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Accounts payable and accrued liabilities
Accounts payable	$ 10,563,496	$ 9,050,616
Accrued liabilities	4,385,207	4,651,014
Total	$ 14,948,703	$ 13,701,630

Loans payable - Bank Loans (Det

Loans payable - Bank Loans (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Loans payable
Short Term	$ 11,419,486
Long Term	131,774,065
Total, net	143,193,551
Unamortized capitalized financing costs	3,058,586
Total	146,252,137
TMS device loans
Loans payable
Short Term	6,696
Total, net	6,696
Total	6,696
Credit Facility
Loans payable
Short Term	0
Long Term	131,595,084
Total, net	131,595,084
Unamortized capitalized financing costs	2,907,505
Total	134,502,589
Promissory notes
Loans payable
Short Term	7,412,790
Long Term	178,981
Total, net	7,591,771
Unamortized capitalized financing costs	151,081
Total	7,742,852
Neuronetics Note
Loans payable
Short Term	4,000,000
Long Term	0
Total, net	4,000,000
Total	$ 4,000,000	$ 5,200,000

Loans payable - TMS Device Loan

Loans payable - TMS Device Loans (Details) - TMS device loans - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2022
Loans payable
Average Interest Rate			9.30%
Average monthly blended payment			$ 1,538
Repayment of loans during the year	$ 52,265	$ 122,010

Loans payable - Madryn Credit F

Loans payable - Madryn Credit Facility (Details)					3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 19, 2024	Jun. 14, 2023 USD ($)	Feb. 21, 2023	Jul. 14, 2022 USD ($) installment	Sep. 30, 2024 USD ($) TRANCHE $ / shares	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) TRANCHE $ / shares	Sep. 30, 2023 USD ($)	Dec. 31, 2022	Nov. 06, 2024 USD ($)	Oct. 15, 2024 USD ($)	Oct. 03, 2024 USD ($)	Dec. 31, 2023 USD ($)	Oct. 13, 2023 USD ($)	Feb. 03, 2023 USD ($)
Loans payable
Basis spread on variable rate							7.65%
Aggregate principal amount										$ 5,106,599	$ 5,106,599	$ 5,106,599		$ 6,505,000	$ 750,000
Madryn Credit Facility [Member]
Loans payable
Aggregate principal amount					$ 120,990,522		$ 120,990,522			$ 5,106,599	$ 5,106,599	$ 5,106,599
Interest rate	0%
Credit Facility
Loans payable
Number of additional tranches | TRANCHE					24		24
Carrying amount of Madryn Credit Agreement					$ 131,595,084		$ 131,595,084						$ 83,943,636
Interest expense					4,433,190	$ 2,542,545	12,241,287
Total deferred financing costs					4,565,584		4,565,584
Financing costs incurred during the year							733,275
Amortization of deferred financing costs					$ 270,981	$ 174,838	$ 705,889	$ 493,004
Effective interest rate					0.86%		0.86%						1.01%
Conversion amount - Maximum							$ 5,000,000
Debt instrument - Conversion price per share | $ / shares					$ 1.9		$ 1.9
Number of shares to be issued on conversion							3,910,604
Amendment fee paid		$ 1,000,000
Credit Facility | SOFR
Loans payable
Basis spread on variable rate			9%
Floor of Variable rate used			1.50%
Rate added to variable rate used			0.10%
Existing loans
Loans payable
Term Loan Principal Amount				$ 55,000,000
Term Loan Additional principal				$ 20,000,000
Maturity term				63 months
Interest only payment term				4 years
Number of 3-month installments | installment				5
Number of installments | installment				3
Existing loans | LIBOR
Loans payable
Basis spread on variable rate									9%
New Loans
Loans payable
Aggregate principal amount					$ 62,949,913		$ 62,949,913
Conversion amount - Maximum							$ 2,430,149
Debt instrument - Conversion price per share | $ / shares					$ 1.9		$ 1.9
New Loans | LIBOR
Loans payable
Floor of Variable rate used									1.50%
Madryn Credit Facility [Member] | Madryn
Loans payable
Aggregate principal amount					$ 118,949,913		$ 118,949,913						$ 82,731,638
Interest expense								$ 7,169,931

Loans payable - Promissory Note

Loans payable - Promissory Notes (Details)				3 Months Ended		9 Months Ended
	Oct. 03, 2024 USD ($) $ / shares shares	Aug. 15, 2023 USD ($)	Jul. 14, 2022 USD ($) ITEM	Sep. 30, 2024 USD ($) $ / shares	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) Day $ / shares	Sep. 30, 2023 USD ($)	Nov. 06, 2024 USD ($)	Oct. 15, 2024 USD ($)	Dec. 31, 2023 USD ($)	Oct. 13, 2023 USD ($)	Aug. 28, 2023 USD ($)	Feb. 03, 2023 USD ($)
Loans payable
Aggregate principal amount	$ 5,106,599							$ 5,106,599	$ 5,106,599		$ 6,505,000		$ 750,000
Common Stock [Member] | Convertible Subordinated Debt [Member]
Loans payable
Debt instrument - Conversion price per share | $ / shares	$ 0.078
Subordinated convertible notes, common shares | shares	134,667,522
Subordinated convertible notes, common per shares | $ / shares	$ 0.078
2023 Notes
Loans payable
Number of promissory notes assumed | ITEM			2
Carrying amount of Madryn Credit Agreement				$ 7,591,771		$ 7,591,771				$ 6,796,861
Interest expense				272,687	$ 56,354	794,911	$ 70,107
Repayment of notes				0	0	$ 0	0
2023 Notes | Officers
Loans payable
Aggregate principal amount												$ 60,000	60,000
2023 Notes | Shareholders
Loans payable
Aggregate principal amount													$ 690,000
2023 Notes | Success TMS Acquisition
Loans payable
Aggregate principal amount			$ 200,000
Interest rate (in %)			5%
Debt instrument fair value - Measurement Input			12%
Convertible Subordinated Debt [Member]
Loans payable
Aggregate principal amount		$ 500,000
Minimum conversion price percentage (in %)						85%
Volume weighted average trading days | Day						30
Financing costs incurred during the year		$ 42,105				$ 184,755
Amortization of deferred financing costs				8,160	10,034	23,331	10,034
Interest expense				129,600	$ 44,282	377,927	$ 44,282
Repayment of notes				$ 0		$ 0
Convertible Subordinated Debt [Member] | Minimum
Loans payable
Debt instrument - Conversion price per share | $ / shares				$ 0.078		$ 0.078
Subordinated convertible notes, common per shares | $ / shares				$ 0.078		$ 0.078
Convertible Subordinated Debt [Member] | Maximum
Loans payable
Number of shares to be issued on conversion						200,000,000

Loans payable - Neuronetics Not

Loans payable - Neuronetics Notes (Details)		3 Months Ended		9 Months Ended
	Mar. 31, 2023 USD ($) Day	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Nov. 06, 2024 USD ($)	Oct. 15, 2024 USD ($)	Oct. 03, 2024 USD ($)	Dec. 31, 2023 USD ($)	Oct. 13, 2023 USD ($)	Feb. 03, 2023 USD ($)
Loans payable
Accounts payable		$ 10,563,496		$ 10,563,496					$ 9,050,616
Face Amount						$ 5,106,599	$ 5,106,599	$ 5,106,599		$ 6,505,000	$ 750,000
Basis spread on variable rate				7.65%
Carrying amount		146,252,137		$ 146,252,137
Neuronetics Note
Loans payable
Accounts payable	$ 5,883,644
Face Amount	$ 6,000,000
Basis spread on variable rate	7.65%
Percentage of unpaid amount used as numerator for issuance of warrants	200%
Discount on exercise price of warrants compared to share price used as denominator for issuance of warrants	20%
Volume weighted average trading days | Day	30
Carrying amount		4,000,000		4,000,000					$ 5,200,000
Interest expense		137,372	$ 188,889	451,907	$ 378,964
Repayment of notes		$ 537,372	$ 533,333	$ 1,651,907	$ 533,333

Loans payable - Non-controlling

Loans payable - Non-controlling interest loans (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Loans payable
Non-controlling interest loans	$ 58,074	$ 63,174
Non-controlling interest loans
Loans payable
Non-controlling interest loans	$ 58,074	$ 63,174
Interest rate, compounded on a monthly basis	10%

Shareholder loans - 2023 and Gr

Shareholder loans - 2023 and Greybrook Notes (Details)			3 Months Ended		9 Months Ended
	Aug. 01, 2023 USD ($) Day shares	Feb. 28, 2023 USD ($) Day $ / shares shares	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) Day	Sep. 30, 2023 USD ($)	Nov. 06, 2024 USD ($)	Oct. 15, 2024 USD ($)	Oct. 03, 2024 USD ($)	Dec. 31, 2023 USD ($)	Oct. 13, 2023 USD ($)	Aug. 15, 2023 USD ($)	Feb. 03, 2023 USD ($)
Debt Instruments
Face Amount							$ 5,106,599	$ 5,106,599	$ 5,106,599		$ 6,505,000		$ 750,000
Gain (Loss) on Extinguishment of Debt				$ (14,274)	$ 39,822	$ (14,274)
Greybrook Health Inc | February 2023 Warrants
Debt Instruments
Number of shares per warrant (in shares) | shares		1
Warrant exercise price (in $ per share) | $ / shares		$ 1.84
Greybrook Health Inc | August 2023 Warrants
Debt Instruments
Number of shares per warrant (in shares) | shares	1
Fair value of warrants	$ 19,728
Related party | Greybrook Health Inc | February 2023 Warrants
Debt Instruments
Number of warrants issued (in shares) | shares		135,870
Number of shares per warrant (in shares) | shares		1
Warrant exercise price (in $ per share) | $ / shares		$ 1.84
Fair value of warrants		$ 63,587
February 2023 and August 2023 Notes
Debt Instruments
Carrying amount			$ 0		0					$ 0
February 2023 and August 2023 Notes | Greybrook Health Inc
Debt Instruments
Total deferred financing costs			109,132		109,132
Amortization of deferred financing costs			0			3,982
Amortization of deferred losses					0	7,656
February 2023 Notes
Debt Instruments
Face Amount													$ 690,000
Interest expense			0	160,940	$ 0	377,088
February 2023 Notes | Greybrook Health Inc
Debt Instruments
Face Amount		1,000,000
February 2023 Notes | Significant Shareholder | Greybrook Health Inc
Debt Instruments
Conversion amount - Maximum		$ 1,000,000
Minimum conversion price percentage (in %)		85%
Volume weighted average trading days | Day		5
August 2023 Notes | Greybrook Health Inc
Debt Instruments
Face Amount	$ 1,000,000
Minimum conversion price percentage (in %)	85%
Volume weighted average trading days | Day	5
Number of warrants issued (in shares) | shares	250,000
Convertible Subordinated Debt [Member]
Debt Instruments
Face Amount												$ 500,000
Minimum conversion price percentage (in %)					85%
Volume weighted average trading days | Day					30
Amortization of deferred financing costs			8,160	10,034	$ 23,331	10,034
Interest expense			$ 129,600	$ 44,282	$ 377,927	$ 44,282

Shareholder loans - Subordinate

Shareholder loans - Subordinated Convertible Notes (Details) - USD ($)			3 Months Ended		9 Months Ended
	Oct. 03, 2024	Aug. 15, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Debt Instruments
Amount of Feb 2023 and August 2023 notes exchanged		$ 3,690,000
Convertible Subordinated Debt [Member] | Common Stock [Member]
Debt Instruments
Debt Conversion, Converted Instrument, Shares Issued	134,667,522
Debt Instrument, Convertible, Conversion Price	$ 0.078
Convertible Subordinated Debt [Member]
Debt Instruments
Carrying value			$ 3,690,568		$ 3,690,568		$ 3,312,641
Repayment of notes			0		0
Financing costs incurred during the year		$ 42,105			184,755
Amortization of deferred financing costs			$ 1,860	$ 803	$ 5,321	$ 803

Other payables - Lender Warrant

Other payables - Lender Warrants (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($)	Sep. 30, 2024 $ / shares	Dec. 31, 2023 USD ($)
Class of Warrant or Right [Line Items]
Change in fair value				$ (6,567)
Oxford Warrants
Class of Warrant or Right [Line Items]
Lender warrants	$ 0		$ 0			$ 0
Issuance of common share purchase warrants | shares			51,307
Each exercisable for one common share | shares	1		1
Exercise price | $ / shares					$ 11.2
Change in fair value	$ 0	$ 0	$ 0	$ 6,567

Other payables - Share Units (D

Other payables - Share Units (Details) - USD ($)			3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 05, 2021	May 06, 2021	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share units granted during the period (in shares)							0
DSUs | DSU Plan for non-employee directors
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Other payables			$ 43,460		$ 43,460		$ 376,565
Minimum Percentage of retainer fee received as DSUs (in %)		50%
Period for payments of cash for awards held					10 days
Share units granted during the period (in shares)			0	469,384	2,588,746	874,601
Value of financial liability			$ 43,460		$ 43,460		376,565
Recovery related to share units recognized in general and administrative expenses			306,856	$ 151,084	$ 333,105	$ 273,938
Minimum price for trading of common share					$ 0.0846
PSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Value of financial liability			0		$ 0		1,047
PSUs | Equity Incentive Plan to employees
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Other payables			0		$ 0		$ 1,047
Vesting of share units in the period (in shares)	38,647				3,865
Change in fair value			$ 0	$ (1,507)	$ (1,047)	$ (43,748)
RSUs | Equity Incentive Plan to employees
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share units granted during the period (in shares)					0

Other payables - Device Contrac

Other payables - Device Contract Termination (Details) - USD ($)		3 Months Ended		9 Months Ended
	Aug. 21, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other payables		$ 1,947,395		$ 1,947,395		$ 5,730,781
Number of weeks for payment of instalments	308 days
Loss on device contract termination			$ 3,181,116		$ 3,181,116
Device Contract Termination
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other payables	$ 6,600,000	0		0		$ 3,750,000
Gain on extinguishment of liabilities	2,030,635
Impairment of ROU assets	5,211,751
Loss on device contract termination	$ 3,181,116	$ 0	$ 3,181,116	$ 0	$ 3,181,116
Interest rate in the event of default (in %)				6%

Other payables - Klein Note Set

Other payables - Klein Note Settlement payable (Details) - USD ($)	Nov. 20, 2023	Nov. 06, 2024	Oct. 15, 2024	Oct. 03, 2024	Sep. 30, 2024	Dec. 31, 2023	Oct. 13, 2023	Feb. 03, 2023	Jul. 14, 2022
Debt Instruments
Aggregate principal amount		$ 5,106,599	$ 5,106,599	$ 5,106,599			$ 6,505,000	$ 750,000
Promissory notes | Benjamin Klein
Debt Instruments
Other payable					$ 0	$ 1,603,169
Aggregate principal amount									$ 2,090,264
Settlement payment to be made	$ 2,228,169
Initial immediate payment	250,000
Average monthly blended payment	$ 75,000

Other payables - PA Settlement

Other payables - PA Settlement Agreement (Details) - USD ($)	Aug. 09, 2024	Sep. 30, 2024	Dec. 31, 2023
Promissory notes | PA Settlement Agreement
Debt Instruments
Loans Payable, Current		$ 533,333	$ 0
PA Settlement Agreement [Member]
Debt Instruments
Plaintiffs cash settlement amount	$ 800,000
Up-front payment	200,000
Monthly installments	67,000
Payment of payroll taxes	$ 110,000
Number of common shares will redeemed	11,634,660
Acquisition issuance (in shares)	2,908,665

Other payables - Neuronetics Tr

Other payables - Neuronetics Transaction Cost (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Schedule of Neuronetics Transaction Costs [Line Items]
Other Liabilities, Current	$ 1,947,395	$ 5,730,781
Arrangement Agreement [Member]
Schedule of Neuronetics Transaction Costs [Line Items]
Other Liabilities, Current	$ 1,370,602	$ 0

Deferred and contingent consi_3

Deferred and contingent consideration (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2021
Business acquisition
Deferred and contingent consideration		$ 1,000,000	$ 1,000,000
Restricted cash held in escrow released to the vendors	$ 250,000
Achieve TMS East, LLC and Achieve TMS Central, LLC
Business acquisition
Deferred and contingent consideration		$ 1,000,000	$ 1,000,000	$ 1,250,000
Restricted cash held in an escrow				$ 1,250,000

Advance for research collabor_3

Advance for research collaboration (Details) - USD ($)		3 Months Ended		9 Months Ended
	Dec. 29, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Advance for research collaboration
Advance for research collaboration						$ 1,300,000
Revenue recognized		$ 200,000	$ 0	$ 1,500,000	$ 0
Research Collaboration Agreement
Advance for research collaboration
Term of agreement	3 years
Total consideration payout upon completion of milestones	$ 3,000,000
Amount received on signing	$ 1,300,000

Common shares - Changes in comm

Common shares - Changes in common shares (Details) - USD ($)	3 Months Ended			9 Months Ended
	Mar. 31, 2024	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2024
Number
Beginning Balance (in shares)	42,774,011			42,774,011
Issuance of common shares (note 14) (in shares)				2,828,249
Surrender and Cancellation of Common Shares – PA Settlement Agreement				(11,634,660)
Ending Balance (in shares)				33,967,600
Total Amount
Beginning Balance	$ 120,741,061			$ 120,741,061
Issuance of common shares (note 14)	$ 495,649	$ 481,437	$ 6,139,262	495,649
Ending Balance				$ 121,236,710

Common shares (Details)

Common shares (Details) - USD ($)				9 Months Ended
	Aug. 12, 2024	Aug. 09, 2024	Feb. 26, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Common shares
Issuance of common shares (note 14) (in shares)				2,828,249
Gross proceeds				$ 495,649	$ 6,620,699
Percentage Of Vote Cast By The Holder Of Common Shares	66.67%
Common shares outstanding				33,967,600		42,774,011
Preferred shares issued
Preferred shares outstanding
Private Placement
Common shares
Issuance of common shares (note 14) (in shares)			2,828,249
Issue price per common share			$ 0.2
Gross proceeds			$ 565,649
Financing costs recorded as a reduction in equity			$ 70,000
PA Settlement Agreement [Member]
Common shares
Issuance of common shares (note 14) (in shares)		11,634,660
Arrangement Agreement [Member]
Common shares
Common share to be exchanged per share	$ 0.01149
Common Stock, Shares, Issued	25,304,971
Percentage Of Common Shares Owned By Madryn	95.30%
Percentage Of Share Issue To The Company Shareholder	95.30%
Mutual termination fee	$ 1,900,000
Common shares outstanding	1,680,718
Percentage of share outstanding	5.55%
Members' Capital	$ 1,315
Diluted basis common stock issued	16,536,208
Percentage of diluted basis common stock issue	48.70%
Cancellation Of Outstanding Common Share	11,634,660
Percentage locked up share outstanding	72.50%
Percentage of premium value of consideration payable	20%
Neuronetics Shareholders [Member] | Arrangement Agreement [Member]
Common shares
Subsidiary, Ownership Percentage, Parent	57%
Companys Shareholders [Member] | Arrangement Agreement [Member]
Common shares
Subsidiary, Ownership Percentage, Noncontrolling Owner	43%

Contributed surplus - Stock Opt

Contributed surplus - Stock Options Narratives (Details) - shares	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding (in shares)	2,219,500	1,704,500	764,667
Employee Stock Option
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period (in years)	3 years
Maximum percentage of shares reserved for future issuance (in %)	10%
Shares reserved for future issuance (in shares)	3,396,760	4,277,401
Outstanding (in shares)	2,219,500	1,704,500
Option expiration period (in years)	10 years
RSU and PSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Maximum percentage of shares reserved for future issuance (in %)	5%

Contributed surplus - Stock O_2

Contributed surplus - Stock Options Outstanding (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Number of stock options
Outstanding, beginning balance	1,704,500	764,667
Granted	575,000	1,313,000
Forfeited	(55,000)	(373,167)
Expired	(5,000)
Outstanding, ending balance	2,219,500	1,704,500
Weighted average exercise price
Outstanding, beginning balance (per share)	$ 3.11	$ 8.15
Granted (per share)	0.1	0.63
Forfeited (per share)	(0.75)	(4.71)
Expired (per share)	(0.75)
Outstanding, ending balance (per share)	$ 2.39	$ 3.11

Contributed surplus - Stock O_3

Contributed surplus - Stock Options - Additional Narratives (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation	$ 51,923	$ 14,740	$ 111,110	$ 591,470
Employee Stock Option
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average contractual life in years			7 years 8 months 15 days		7 years 10 months 20 days
Options exercisable (in shares)	1,277,749		1,277,749		1,087,164
Share-based compensation	$ 51,923	$ 14,740	$ 111,110	$ 591,470
Total compensation cost not yet recognized	$ 86,166		$ 86,166		$ 183,312
Compensation cost not recognized - period of recognition (in years)			1 year 1 month 6 days		1 year 10 days

Contributed surplus - Greybrook

Contributed surplus - Greybrook Warrants (Details) - Greybrook Health Inc	Aug. 01, 2023 USD ($) $ / shares shares	Feb. 28, 2023 yr $ / shares shares	Sep. 30, 2024 shares	Dec. 31, 2023 shares
February 2023 Warrants
Contributed surplus
Issuance of common share purchase warrants		135,870
Each exercisable for one common share		1
Exercise price | $ / shares		$ 1.84
Fair value per warrant (in $ per share) | $ / shares		$ 0.47
February 2023 Warrants | Volatility
Contributed surplus
Warrant measurement input		0.4886
February 2023 Warrants | Remaining life
Contributed surplus
Warrant measurement input | yr		5
February 2023 Warrants | Expected dividend yield
Contributed surplus
Warrant measurement input		0
February 2023 Warrants | Forfeiture rate
Contributed surplus
Warrant measurement input		0
February 2023 Warrants | Risk free interest rate
Contributed surplus
Warrant measurement input		0.0418
August 2023 Warrants
Contributed surplus
Issuance of common share purchase warrants	250,000
Each exercisable for one common share	1
Exercise price as percentage of stock price (in %)	85%
Warrant threshold trading days required (in days)	5 days
Lender warrants | $	$ 19,728
Share price (in $ per share) | $ / shares	$ 0.5
Share price based on five trading days (in $ per share) | $ / shares	$ 0.49
Weighted average contractual life (in years)			3 years 8 months 12 days	4 years 4 months 24 days
Warrants exercisable			385,870	385,870

Pensions (Details)

Pensions (Details) - Pension plan - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pensions
Matching contribution made by company			3.50%
Contributions for the year	$ 244,287	$ 177,391	$ 690,248	$ 553,300

Risk management arising from _3

Risk management arising from financial instruments - Aging schedule in respect of accounts receivable balance (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net	$ 12,628,278	$ 7,569,843
0 - 90
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net	10,592,724	5,954,636
91 - 180
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net	1,279,098	1,013,083
181 - 270
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net	487,503	379,772
270+
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net	$ 268,953	$ 222,352

Risk management arising from _4

Risk management arising from financial instruments - Interest rate risk (Details)	9 Months Ended
	Sep. 30, 2024 USD ($)
Debt Instrument [Line Items]
Basis spread on variable rate	7.65%
Percentage of possible increase in interest rate	1%
Amount of increase in interest expense	$ 51,667

Related party transactions - Tr

Related party transactions - Transactions with significant shareholder - Greybrook Health (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Related party transactions
Corporate, general and administrative expense	$ 6,291,658	$ 5,986,061	$ 21,470,073	$ 21,405,122
Greybrook Health Inc
Related party transactions
Accounts payables and accrued liabilities	0		0		$ 4,884
Corporate, general and administrative expense	$ 0	$ 1,788	$ 0	$ 5,011

Related party transactions - Lo

Related party transactions - Loans from shareholder - Greybrook Health (Details) - USD ($)

3 Months Ended

9 Months Ended

Oct. 03, 2024

Aug. 28, 2023

Sep. 30, 2024

Sep. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

Nov. 06, 2024

Oct. 15, 2024

Dec. 31, 2023

Oct. 13, 2023

Aug. 15, 2023

Feb. 03, 2023

Related party transactions

Aggregate principal amount

$ 5,106,599

$ 5,106,599

$ 5,106,599

$ 6,505,000

$ 750,000

Common Stock [Member] | Convertible Subordinated Debt [Member]

Related party transactions

Subordinated convertible notes, common shares

134,667,522

Subordinated convertible notes, common per shares

$ 0.078

February 2023 and August 2023 Notes

Related party transactions

Note payable

$ 0

$ 0

$ 0

February 2023 Notes

Related party transactions

Aggregate principal amount

$ 690,000

Interest expense

0

$ 160,940

0

$ 377,088

Greybrook Health Inc | Common Stock [Member] | Convertible Subordinated Debt [Member]

Related party transactions

Subordinated convertible notes, common shares

43,739,148

Subordinated convertible notes, common per shares

$ 0.078

Greybrook Health Inc | February 2023 and August 2023 Notes

Related party transactions

Note payable

$ 2,437,604

Aggregate principal amount

$ 2,437,604

Interest expense

$ 119,501

$ 92,333

$ 348,470

$ 166,362

Greybrook Health Inc | Subordinate convertible note

Related party transactions

Note payable

$ 500,000

Greybrook Health Inc | February 2023 Warrants | February 2023 Notes

Related party transactions

Number of warrants issued (in shares)

135,870

Greybrook Health Inc | August 2023 Warrants | August 2023 Notes

Related party transactions

Number of warrants issued (in shares)

250,000

Related party transactions - _2

Related party transactions - Transactions with the significant shareholder, officer and director - Benjamin Klein (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Related party transactions
Corporate, general and administrative expense	$ 6,291,658	$ 5,986,061	$ 21,470,073	$ 21,405,122
Benjamin Klein
Related party transactions
Corporate, general and administrative expense	0	$ 76,921	0	$ 229,178
Accounts payables and accrued liabilities	$ 0		$ 0		$ 0

Related party transactions - _3

Related party transactions - Loan from significant shareholder, officer and director - Benjamin Klein (Details) - USD ($)		3 Months Ended		9 Months Ended
	Jul. 14, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Nov. 06, 2024	Oct. 15, 2024	Oct. 03, 2024	Dec. 31, 2023	Oct. 13, 2023	Feb. 03, 2023
Related party transactions
Aggregate principal amount						$ 5,106,599	$ 5,106,599	$ 5,106,599		$ 6,505,000	$ 750,000
Klein Note
Related party transactions
Aggregate principal amount	$ 2,090,264	$ 0		$ 0					$ 0
Interest rate	10%
Benjamin Klein | Klein Note
Related party transactions
Interest expense		$ 0	$ 64,175	$ 0	$ 191,485

Related party transactions - _4

Related party transactions - Loans from shareholders and officers (Details) - USD ($)		3 Months Ended		9 Months Ended
	Oct. 03, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Nov. 06, 2024	Oct. 15, 2024	Dec. 31, 2023	Oct. 13, 2023	Feb. 28, 2023	Feb. 03, 2023
Related party transactions
Aggregate principal amount	$ 5,106,599					$ 5,106,599	$ 5,106,599		$ 6,505,000		$ 750,000
Common Stock [Member] | Convertible Subordinated Debt [Member]
Related party transactions
Subordinated convertible notes, common shares	134,667,522
Subordinated convertible notes, common per shares	$ 0.078
February 2023 Notes
Related party transactions
Aggregate principal amount											$ 690,000
Interest expense		$ 0	$ 160,940	$ 0	$ 377,088
Benjamin Klein | Subordinate convertible note
Related party transactions
Aggregate principal amount		335,318		335,318				$ 328,026
Interest expense		$ 11,499	$ 14,323	$ 33,542	$ 32,654
Benjamin Klein | Subordinate convertible note | Common Stock [Member] | Convertible Subordinated Debt [Member]
Related party transactions
Subordinated convertible notes, common shares	1,115,728
Subordinated convertible notes, common per shares	$ 0.078
Benjamin Klein | February 2023 Notes
Related party transactions
Aggregate principal amount										$ 312,396

Related party transactions - _5

Related party transactions - Loan from significant shareholder - Madryn (Details) - USD ($)		3 Months Ended		9 Months Ended
	Oct. 03, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Nov. 06, 2024	Oct. 15, 2024	Dec. 31, 2023	Oct. 13, 2023	Oct. 12, 2023	Feb. 03, 2023
Related party transactions
Aggregate principal amount	$ 5,106,599					$ 5,106,599	$ 5,106,599		$ 6,505,000		$ 750,000
Common Stock [Member] | Convertible Subordinated Debt [Member]
Related party transactions
Subordinated convertible notes, common shares	134,667,522
Subordinated convertible notes, common per shares	$ 0.078
Madryn | Subordinate convertible note
Related party transactions
Aggregate principal amount										$ 4,500,000
Interest expense		$ 187,366	$ 47,044	$ 546,061	$ 47,044
Madryn | Madryn Credit Facility
Related party transactions
Aggregate principal amount		118,949,913		118,949,913				$ 82,731,638
Interest expense					$ 7,169,931
Amendment fee		$ 1,000,000		$ 1,000,000
Madryn Fund Administration LLC And Affiliated Entities [Member] | Common Stock [Member] | Convertible Subordinated Debt [Member]
Related party transactions
Subordinated convertible notes, common shares	57,692,306
Subordinated convertible notes, common per shares	$ 0.078

Basic and diluted loss per sh_3

Basic and diluted loss per share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Basic and diluted loss per share
Net loss attributable to the common shareholders of Greenbrook TMS, basic	$ (13,207,359)	$ (13,491,287)	$ (39,830,850)	$ (36,824,871)
Net loss attributable to the common shareholders of Greenbrook TMS, diluted	$ (13,207,359)	$ (13,491,287)	$ (39,830,850)	$ (36,824,871)
Weighted average common shares outstanding, basic (in shares)	39,721,003	42,232,942	43,061,687	37,810,209
Weighted average common shares outstanding, diluted (in shares)	39,721,003	42,232,942	43,061,687	37,810,209
Loss per share, basic (in dollars per share)	$ (0.33)	$ (0.32)	$ (0.92)	$ (0.97)
Loss per share, diluted (in dollars per share)	$ (0.33)	$ (0.32)	$ (0.92)	$ (0.97)

Basic and diluted loss per sh_4

Basic and diluted loss per share - Antidilutive securities excluded from diluted calculation (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Employee Stock Option
Antidilutive securities excluded from diluted calculation
Antidilutive securities excluded from diluted calculation	2,219,500	1,661,500	2,219,500	1,661,500
Lender warrants
Antidilutive securities excluded from diluted calculation
Antidilutive securities excluded from diluted calculation	437,177	437,177	437,177	437,177

Non-controlling interest (Detai

Non-controlling interest (Details) - USD ($)	Sep. 29, 2023	Sep. 30, 2024	Dec. 31, 2023
Greenbrook TMS Inc and Subsidiaries
Non-controlling interest
Ownership percentage		100%
Greenbrook TMS Connecticut LLC
Non-controlling interest
Ownership percentage		100%
Greenbrook TMS Arlington LLC [Member]
Non-controlling interest
Ownership percentage			100%
Consideration transferred on purchase of non controlling interest	$ 513
Consideration transferred on repayment of non controlling interest loan	39,487
Release of liabilities and losses	$ 40,000
Greenbrook TMS Fairfax LLC [Member]
Non-controlling interest
Ownership percentage		100%
Greenbrook TMS Greenbelt LLC [Member]
Non-controlling interest
Ownership percentage		87.50%
Greenbrook TMS Christiansburg LLC
Non-controlling interest
Ownership percentage		100%
Greenbrook TMS Lynchburg LLC
Non-controlling interest
Ownership percentage		100%
Greenbrook TMS Roanoke LLC
Non-controlling interest
Ownership percentage		100%
NeuroHealth Centers St. Petersburg LLC
Non-controlling interest
Ownership percentage		100%
NeuroHealth Centers Mooresville LLC
Non-controlling interest
Ownership percentage		100%
NeuroHealth Centers Woodbridge LLC
Non-controlling interest
Ownership percentage		100%
NeuroHealth Centers Wilmington LLC
Non-controlling interest
Ownership percentage		100%

Non-controlling interest - Sche

Non-controlling interest - Schedule of balance sheet financial information of non-controlling interest (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Non-controlling interest
Cash	$ 368,512	$ 3,323,708
Accounts receivable, net	12,628,278	7,569,843
Property, plant and equipment	4,725,435	4,793,979
Finance right-of-use assets	1,276,821	2,140,338
Operating right-of-use assets	23,658,188	28,887,905
Accounts payable and accrued liabilities	14,948,703	13,701,630
Finance lease liabilities	375,695	857,837
Operating lease liabilities	25,182,412	30,398,566
Shareholder's deficit attributable to the shareholders of Greenbrook TMS	(136,915,624)	(98,036,209)
Shareholder's deficit attributable to non-controlling interest	(3,603,068)	(2,911,581)
Non-controlling interest
Non-controlling interest
Cash	172,341	97,702
Accounts receivable, net	4,977,643	2,144,953
Prepaid expenses and other	408,155	297,485
Property, plant and equipment	924,260	1,000,592
Finance right-of-use assets		36,165
Operating right-of-use assets	5,310,005	5,656,153
Accounts payable and accrued liabilities	1,597,561	1,239,917
Finance lease liabilities		10,548
Operating lease liabilities	5,622,097	5,968,042
Loans payable, net	16,534,707	15,828,916
Shareholder's deficit attributable to non-controlling interest	(4,258,434)	(4,440,274)
Distributions paid to non-controlling interests	(201,000)	(46,950)
Partnership buyout	(466,026)	253,251
Historical subsidiary investment by non-controlling interest	1,322,392	1,322,392
Parent
Non-controlling interest
Shareholder's deficit attributable to the shareholders of Greenbrook TMS	$ (8,358,893)	$ (10,902,792)

Non-controlling interest - Sc_2

Non-controlling interest - Schedule of comprehensive loss financial information of non-controlling interest (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Non-controlling interest
Net loss attributable to the shareholders of Greenbrook TMS	$ (13,207,359)	$ (13,491,287)	$ (39,830,850)	$ (36,824,871)
Net loss attributable to non-controlling interest	328,018	(66,025)	(24,461)	(249,575)
Non-controlling interest
Non-controlling interest
Revenue	8,337,782	5,561,769	20,184,728	18,473,712
Net loss attributable to non-controlling interest	328,018	(66,025)	(24,461)	(249,575)
Parent
Non-controlling interest
Net loss attributable to the shareholders of Greenbrook TMS	$ 474,492	$ (311,254)	$ (776,242)	$ (1,353,456)

Expenses by nature - Other regi

Expenses by nature - Other regional and center support costs (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating Expenses [Abstract]
Salaries and bonuses	$ 5,506,017	$ 4,356,592	$ 16,703,081	$ 13,129,558
Marketing expenses	1,717,372	407,538	3,941,952	1,224,139
Total	$ 7,223,389	$ 4,764,130	$ 20,645,033	$ 14,353,697

Expenses by nature (Details)

Expenses by nature (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating Expenses [Abstract]
Salaries and bonuses	$ 3,760,881	$ 3,629,623	$ 11,671,760	$ 11,880,351
Marketing expenses	49,676	52,237	171,400	83,504
Professional and legal fees	1,119,518	937,735	2,730,955	3,565,048
Computer supplies and software	938,265	659,320	3,503,319	2,091,340
Financing and transaction costs	13,185	100,000	174,662	335,094
Travel, meals and entertainment	62,539	39,994	185,187	121,181
Restructuring expense		36,500	684,578	500,368
Insurance	51,088	113,909	377,078	476,687
Credit facility amendment fee		0		1,000,000
PA Settlement Agreement (note 11(f))	0		800,000
Other	296,506	416,743	1,171,134	1,351,549
Total	$ 6,291,658	$ 5,986,061	$ 21,470,073	$ 21,405,122

Preliminary Purchase Price Al_3

Preliminary Purchase Price Allocation - Schedule of Fair value of the total consideration (Details) - Pro Forma [Member]	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
STIM Shares | shares	25,305
Price per share | $ / shares	$ 1.15
Fair value of purchase consideration paid at closing	$ 29,101,000
Settlement of pre- existing relationship	5,635
Total purchase consideration	$ 34,736,000

Preliminary Purchase Price Al_4

Preliminary Purchase Price Allocation - Schedule of Fair value of the total consideration (Parenthectical) (Details) $ in Millions	Sep. 30, 2024 USD ($)
Pro Forma [Member]
Total consideration	$ 34.7

Preliminary Purchase Price Al_5

Preliminary Purchase Price Allocation - Schedule of Preliminary allocation of the total consideration (Details) - Pro Forma [Member] $ in Thousands	Sep. 30, 2024 USD ($)
Fair value of assets acquired
Cash and cash equivalents	$ 369
Restricted cash	1,000
Accounts receivable, net	12,628
Prepaid expenses and other current assets	4,990
Property and equipment	4,725
Operating lease right-of-use assets	23,658
Total Assets	47,370
Fair value of liabilities assumed
Accounts payable	8,673
Accrued expense	4,385
Current portion of loans payable	801
Current portion of operating lease liabilities	4,044
Deferred and contingent consideration	1,000
Operating lease liabilities	21,139
Non-controlling interest	(3,603)
Total Liabilities	36,438
Total identifiable net assets acquired	10,932
Goodwill	23,803
Total consideration transferred	$ 34,736

Proforma Adjustments (Details)

Proforma Adjustments (Details) - Pro Forma [Member]	Dec. 09, 2024 $ / shares shares
Common stock, shares issued | shares	25,304,971
Common stock, per share | $ / shares	$ 1.15

Subsequent event (Details)

Subsequent event (Details)	Dec. 10, 2024 shares	Nov. 15, 2024	Nov. 06, 2024 USD ($) TRANCHE	Oct. 15, 2024 USD ($) TRANCHE	Oct. 03, 2024 USD ($) TRANCHE $ / shares shares	Nov. 27, 2024 USD ($)	Nov. 26, 2024 USD ($)	Sep. 30, 2024 USD ($)	Oct. 13, 2023 USD ($)	Feb. 03, 2023 USD ($)
Subsequent event
Aggregate principal amount | $			$ 5,106,599	$ 5,106,599	$ 5,106,599				$ 6,505,000	$ 750,000
Common Stock [Member] | Convertible Subordinated Debt [Member]
Subsequent event
Subordinated convertible notes, common shares					134,667,522
Debt instrument - Conversion price per share | $ / shares					$ 0.078
Supplement Restructuring Plan [Member] | Other Restructuring [Member]
Subsequent event
Restructuring and related activities description		Company plans to decrease its operating footprint by closing 23 treatment centers over the next 45 days, allowing management to focus on its remaining 95 treatment centers.
Madryn Credit Facility
Subsequent event
Number of additional tranches | TRANCHE			2	2	2
Aggregate principal amount | $			$ 5,106,599	$ 5,106,599	$ 5,106,599			$ 120,990,522
Minimum liquidity covenant | $						$ 300,000	$ 3,000,000
Neuronetics, Inc
Subsequent event
Stock converted during period shares acquisitions	2,056,453,835
Percentage of acquisite company stock converted during period shares acquisitions	0.953
Additional stock converted during period shares acquisitions	252,999,770

Description of the Transaction

Description of the Transaction (Details) - Pro Forma [Member]	Sep. 30, 2024 $ / shares shares
Common share to be exchanged per share | $ / shares	$ 0.01021
Common share outstanding in greenbrook | shares	2,056,453,835
Percentage of common share outstanding in greenbrook | $ / shares	$ 95.3
Additional common share provided by madryn | shares	252,999,770